Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4787 companies, A–Z).
Capstone Holding Corp. agreed with lender 3i, LP to push the maturity of its remaining convertible note from October 22, 2026 to December 13, 2027, with about $900,000 in principal outstanding. The lender also agreed not to enforce existing defaults before the new maturity date, and the company extended its common stock purchase agreement with Tumim Stone Capital, LLC, which is tied to up to $20,000,000 of share sales. The deal eases near-term debt repayment pressure, but the note's conversion rights remain unchanged and the press release lists going-concern risk among its forward-looking statements.
Note maturity moved from October 22, 2026 to December 13, 2027; about $900,000 principal outstanding as of November 6, 2026.
Lender will not enforce defaults arising on or before November 6, 2026 before the new maturity, and no default interest or late charges accrue through that date on those defaults.
Tumim Stone purchase agreement term extended from July 1, 2027 to January 1, 2028; the agreement covers up to $20,000,000 of common stock.
Press release says about 87% of the original $6.8 million in convertible note principal has been retired.
Innovative Industrial Properties amended its equity distribution agreements to add its 9.25% Series B Cumulative Redeemable Preferred Stock to its at-the-market offering program, alongside common stock and 9.00% Series A Preferred Stock. About $336.9 million of the program's $500 million capacity remained available as of the filing date, which gives the company a path to issue more shares that could dilute existing holders.
Program covers common stock, Series A Preferred Stock and Series B Preferred Stock, with aggregate offering price of up to $500 million
Approximately $336.9 million remained available for sale under the ATM Prospectus Supplement dated November 9, 2026
Amendments were entered into November 9, 2026 with BTIG, Piper Sandler, Roth Capital, Stifel, A.G.P./Alliance Global Partners and Huntington Securities
SS&C Technologies completed a private offering of $1.2 billion of 2.75% convertible senior notes due December 1, 2031, including a $150 million option exercised in full by the initial purchasers. The company plans to use the proceeds for capped call transactions, share repurchases of about $100 million, and redeeming its $2.0 billion of 5.500% Senior Notes due 2027, which adds debt and creates potential dilution if the notes convert.
Notes issued November 6, 2026 under an indenture with Wilmington Trust, National Association, as trustee, bearing interest at 2.75% payable June 1 and December 1.
Initial conversion price of about $99.46 per share, a premium of about 25.0% over the $79.57 closing price on November 4, 2026.
Proceeds planned for about $99 million capped call cost, about $100 million of share repurchases (about 1.3 million shares), and redemption of the $2,000.0 million 2027 Senior Notes.
Company may not redeem the notes before December 5, 2029, except in a cleanup redemption.
Jasper Therapeutics announced the results of its offer to purchase all outstanding warrants issued in its September 18, 2025 underwritten public offering, at $0.324 in cash per warrant, which expired on November 7, 2026. A total of 8,510,658 warrants were properly tendered, about 68.94% of the outstanding warrants, and the company expects to pay $2,757,453.19 in cash for them.
8,510,658 warrants were properly tendered and not withdrawn, about 68.94% of outstanding warrants.
Offer price was $0.324 in cash per warrant, without interest; the offer expired at 12:00 a.m. Eastern Time on November 7, 2026.
The company expects to pay an aggregate of $2,757,453.19 in cash, to be made promptly.
The offer was described in a Schedule TO originally filed with the SEC on October 7, 2026.
In the week of November 2 to November 8, 2026, Strategy reported $283.8 million in net proceeds from sales of its MSTR Class A common stock under its at-the-market program, and used $81.9 million of those proceeds to buy 1,036 bitcoin. It also spent $188.3 million repurchasing STRC preferred stock and held $146.2 million in USD Cash as of November 8.
MSTR common stock sales: 2,051,348 shares, $283.8 million net proceeds, with $18.3 billion still available for issuance
Bitcoin: 1,036 bitcoin bought for $81.9 million; aggregate holdings reached 850,364 bitcoin at an average purchase price of $75,456
STRC preferred repurchases: 1,887,464 shares for $188.3 million; $560.3 million remains under the preferred repurchase program
USD Reserve stood at $4.77 billion as of November 8, 2026, after $21.1 million was used for preferred dividends
On November 5, 2026, Inovio agreed to sell 58,747,235 common shares at $1.05 each and pre-funded warrants for 12,681,337 shares at $1.049 each, and on November 6 the underwriters exercised their option to buy 10,714,285 more shares in full. Net proceeds are expected to be about $80.5 million, with closing expected on or about November 9, 2026. The sale adds to the shares outstanding, which dilutes existing holders, but the company says the proceeds and current cash will fund operations into late fourth quarter 2027.
58,747,235 common shares sold at $1.05 per share, plus pre-funded warrants for 12,681,337 shares at $1.049 each
Underwriters exercised their option for 10,714,285 additional shares in full on November 6, 2026
Net proceeds expected to be about $80.5 million; closing expected on or about November 9, 2026
Company believes proceeds and current cash will fund operations into late fourth quarter 2027
Atea Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on November 6, 2026, providing for senior secured term loans of up to $200.0 million, with $65.0 million drawn at closing. The loans mature on November 1, 2031, and are secured by substantially all of the company's assets, including its intellectual property, which gives shareholders a larger fixed debt obligation tied to the company's development of BEM/RZR.
Tranche 1 loan of $65.0 million was drawn on the November 6, 2026 closing date; further tranches total up to $135.0 million
Interest floats at the greater of the WSJ prime rate plus 2.35% or 9.35%, paid monthly, with interest-only payments for 48 months
Tranche 2 availability depends on completing the Phase 3 trial of BEM/RZR before a specified date in the second half of 2027
Financial covenants include a minimum cash test beginning October 1, 2027, and a performance covenant tied to FDA approval of BEM/RZR
Akamai announced a proposed private offering of $1.1 billion of 2028 convertible senior notes and $1.1 billion of 2031 convertible senior notes, subject to market conditions. On November 5, 2026, it also amended its credit agreement, raising the maximum leverage ratio covenant and tightening the limit on secured subsidiary debt, which the filing says applies through March 31, 2028.
Two $1.1 billion offerings: 2028 notes maturing November 15, 2028, and 2031 notes maturing November 15, 2031, with an option for initial purchasers to buy up to an additional $150.0 million of each series.
Proceeds are intended to repay part of the $1.15 billion 0.375% convertible notes due September 1, 2027, fund Cloud Infrastructure Services capital expenditures, pay hedge costs, and for general corporate purposes.
Fourth Amendment dated November 5, 2026, with JPMorgan Chase Bank, N.A. as agent, sets the maximum leverage ratio at 6.25:1.00 for quarters ending December 31, 2026 and March 31, 2027, stepping down to 3.75:1.00 for the quarter ending March
Akamai states there is no assurance the offering will be completed on the anticipated terms, or at all; pricing terms are yet to be set.
Precision BioSciences said it expects its November 5, 2026 share offering, along with existing cash, its at-the-market facility and continued cost discipline, to fund operations into the fourth quarter of 2029. The company projects it is sufficiently capitalized to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points. The filing does not state the net proceeds amount.
Offering of 10,235,077 common shares at $7.75 per share, under an underwriting agreement dated November 5, 2026
Pre-funded warrants for up to 5,893,964 shares offered in lieu of common stock to certain investors, at $7.749995 per warrant
Expected cash runway into the fourth quarter of 2029, covering PBGENE-HBV and PBGENE-DMD programs
Vivid Seats reported third-quarter 2026 revenue of $126.9 million, down from $136.4 million a year earlier, while its net loss narrowed to $17.4 million from $19.7 million and adjusted EBITDA rose to $8.9 million from $4.9 million. The company also reached an agreement in principle with an ad hoc group of term lenders on a recapitalization that would provide $60 million of new money term loans, convert a significant portion of existing debt into equity, and cut funded debt by about $200 million, subject to definitive documentation.
Q3 2026 revenue was $126.9 million versus $136.4 million in Q3 2025; net loss was $17.4 million versus $19.7 million.
Adjusted EBITDA was $8.9 million versus $4.9 million; Marketplace GOV was $624.0 million versus $618.1 million.
Proposed transaction includes $60 million of new money term loans, conversion of a significant portion of debt into equity, a reduction of about $200 million in funded debt, and an extended maturity on remaining debt.
2026 outlook was continued: Marketplace GOV of $2.3 billion to $2.6 billion and adjusted EBITDA of $34.0 million to $40.0 million; the transaction remains subject to definitive documentation.
SBA Communications entered a $2.0 billion senior unsecured Term Loan Credit Agreement on November 6, 2026. The company intends to use the $1.165 billion of initial term loans, funded at closing, to repay its Secured Tower Revenue Securities, Series 2021-1C, while $835.0 million of delayed draw commitments remain available until May 6, 2027.
Total facility of $2.0 billion: $1.165 billion funded on November 6, 2026 and $835.0 million of delayed draw term loan commitments
Initial term loans will repay the entire $1.165 billion of Secured Tower Revenue Securities, Series 2021-1C
Term loans mature November 6, 2029, do not amortize and can be prepaid without premium or penalty
Covenants include a Consolidated Total Net Leverage Ratio not to exceed 7.50 to 1.00 and a Consolidated Senior Secured Leverage Ratio not to exceed 3.50 to 1.00
CKX Lands and Jacobs Private Equity II agreed to a definitive investment agreement providing for a $1 billion cash equity investment in CKX. After closing, JPE will be the controlling stockholder and Brad Jacobs will become chairman and CEO, and the filing describes substantial dilution from convertible preferred stock and warrants. The deal requires CKX stockholder approval and is expected to close in early 2027.
$1 billion total investment: $900 million from JPE and $100 million from co-investors led by HRTG Partners
Upon closing, JPE will hold a majority stake and Brad Jacobs will become chairman and CEO of CKX
Investors would receive convertible preferred stock convertible into about 219 million common shares at $4.57 per share, plus warrants for about 219 million shares
CKX will declare an aggregate cash dividend of $20.8 million, or $10.1312 per share, with a record date shortly before closing; closing is expected in early 2027
FTAI Aviation's subsidiary issued $1.0 billion of 7.125% Senior Notes due November 15, 2034, on November 6, 2026. Net proceeds will repay its revolving credit facility, which was used to fund the parent's accelerated share repurchase program, and redeem $500.0 million of 5.50% notes due 2028.
Proceeds: repay in full the Revolving Credit Facility without a reduction in commitments, redeem $500.0 million of 5.50% Senior Notes due 2028, and pay fees
Notes are senior unsecured, fully guaranteed by FTAI Aviation Ltd., and offered only to qualified institutional buyers and non-U.S. persons
Valion Bio, Inc. issued 700 Series B Preferred Shares and warrants for 21,539 common shares to investor 3i, LP for $700,000 on November 6, 2026, under a side letter to an earlier agreement. The company also agreed to register the resulting common shares for resale and extended the deadline for further closings to December 9, 2027, which may add future dilution for shareholders.
Closing purchase price: $700,000 for 700 Series B Preferred Shares and warrants
Warrants cover 21,539 shares of common stock at an initial exercise price of $0.5182 per share
Registration statement to be filed within 30 days after closing and declared effective within 60 days
Outside date for closings under the Series B Preferred Purchase Agreement extended to December 9, 2027
Hyperscale Data entered a note purchase agreement dated November 6, 2026 with an institutional investor for convertible notes with an aggregate face amount of $27,027,027.03, including original issue discount. The first note closed the same day, and the notes convert into Class A common stock at a discount to market price, which could dilute existing shareholders.
Initial note: $10,810,810.81 principal for a $10,000,000 purchase price, closed November 6, 2026
Second note: $5,405,405.41 principal for a $5,000,000 purchase price, expected on or around November 16, 2026
Conversion at the lower of $0.30 or a 10% discount to the lowest 5-day VWAP, with a $0.1025 floor; issuance capped at 19.99% of outstanding shares unless stockholders approve
Notes accrue 8% interest and mature February 5, 2027, extending to May 5, 2027 after stockholder approval
Mangoceuticals' sole Series B preferred holder approved terms for a new 8% Series D convertible cumulative preferred stock and an amendment to the Series B designation, which would allow the company to sell up to 1,000,000 shares at $10.00 each under Regulation A. The company said the instruments are not yet filed or effective and it may not proceed with the offering; the company also set its combined 2025 and 2026 annual meeting for December 30, 2026.
On November 2, 2026, the holder of all 50 outstanding Series B preferred shares approved the Series D terms and Series B amendment by written consent.
Proposed Series D offering: up to 1,000,000 shares at $10.00 per share under Regulation A; no sales will occur before the SEC qualifies the offering statement on Form 1-A.
Annual meeting set for December 30, 2026 in Dallas, Texas; record date is November 12, 2026.
Shareholder proposals and director nominations for the meeting are due by November 16, 2026.
Clean Energy Technologies, Inc. sold FuFront AI Pte. Ltd. a convertible promissory note with a principal amount of $2,000,000 for the same purchase price, with funding received and the transaction closed on November 4, 2026. The note carries 12% annual interest, matures October 3, 2027, and can convert into common stock at a discount to recent trading prices, which could dilute existing shareholders.
Principal of $2,000,000 at a purchase price of $2,000,000; closed November 4, 2026
Interest accrues at 12% per annum; note matures October 3, 2027
Convertible six months after issuance at 85% of the lowest traded price over the prior ten trading days
Conversion limited to 4.99% beneficial ownership, and to 2,432,004 aggregate shares absent Nasdaq Rule 5635(d) shareholder approval; holder deducts $1,750 per conversion for fees
RenX Enterprises exchanged $1,022,971.22 of principal and accrued interest under a February 12, 2026 senior convertible note for a new senior convertible note of $1,037,283.93 and a warrant to buy 644,944 shares, both issued November 2, 2026. The new note carries 10% interest and a 12-month maturity, and it can convert at $2.895 per share, with a possible alternate conversion price tied to a $0.534 floor once stockholders approve, which could add substantial share issuance for existing holders.
Exchanged $1,022,971.22 of the February 12, 2026 note for a new note of $1,037,283.93, equal to 110% of the prior note's outstanding principal.
New note bears 10% interest, matures in 12 months, and has an initial conversion price of $2.895 per share.
Alternate conversion, available after stockholder approval, is priced at the greater of a $0.534 floor and 92% of the lowest 10-day VWAP.
Warrant has a $2.67 exercise price and a six-year term; default interest rises to 18% per annum if an event of default occurs.
BioVie Inc. agreed on November 3, 2026 to sell shares and pre-funded warrants in a registered direct offering and common warrants in a concurrent private placement, with aggregate gross proceeds of approximately $4.74 million before fees and expenses. The offering closed on November 5, 2026, and the company intends to use the net proceeds for working capital and general corporate purposes. The deal adds shares and dilutive warrants, and the company has agreed to restrictions on new share issuances.
Registered direct offering: 960,000 shares at $1.60 per share plus 2,002,500 pre-funded warrants at $1.5999 each
Concurrent private placement: 2,962,500 common warrants exercisable at $1.70 per share, starting six months after issuance
Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
Company and directors and officers agreed to issuance and sale restrictions for 60 days after the November 5, 2026 closing
Silo Pharma, Inc. entered into securities purchase agreements on November 5, 2026, and closed a private placement with accredited investors on November 6, 2026. The company expects net proceeds of approximately $815,000 for working capital and general corporate purposes, and it agreed to register the resale of the shares and warrant shares with the SEC, which adds potential future share supply for existing shareholders.
Sold 136,005 shares of common stock at $1.50 per share
Issued pre-funded warrants for up to 430,661 shares of common stock at $1.4999 per warrant
Expected net proceeds of approximately $815,000 after placement agent fees and offering expenses
Must file a resale registration statement within 30 days of the November 5, 2026 registration rights agreement, with effectiveness targeted within 60 days (90 days if the SEC conducts a full review)
Reed's, Inc. entered into a third amendment to its senior secured loan with Whitebox-affiliated lenders and Cantor Fitzgerald, adding new liquidity and equity-contribution conditions. The company must receive at least $2,500,000 in cash equity contributions by November 20, 2026, or an Event of Default will occur, and it must also pay a $25,000 extension fee by that date. The company said a delay in its previously announced private placement pushed the expected closing to on or before November 20, 2026, and it has so far received $7,500,000 in gross proceeds from that placement.
Minimum liquidity covenant of not less than $11,000,000 in Cash / Inventory / AR Liquidity, tested at any time and monthly after the Increased Liquidity Period
New Event of Default if at least $2,500,000 in cash equity contributions is not received by November 20, 2026
Non-refundable $25,000 extension fee due on or before November 20, 2026; nonpayment is an Event of Default
Private placement agreement dated October 28, 2026; $7,500,000 gross proceeds received to date
TuHURA Biosciences borrowed an additional $1.5 million on November 2, 2026, under the revolving credit facility from its April 21, 2026 Loan Agreement with Parkview Holdings One LLC. The facility has a maximum availability of $50 million and matures on April 21, 2031, and the company says it will use the funds for general corporate purposes.
Draw of $1,500,000 received and borrowed on November 2, 2026
Revolving facility with Parkview Holdings One LLC has maximum availability of $50 million
Facility matures April 21, 2031; the Loan Agreement was originally entered into April 21, 2026
Filing notes potential conflicts of interest because the lender is an affiliate of the company's largest stockholder
Santander Holdings USA, Inc. (SHUSA) said it will redeem all 6,000 outstanding shares of its Series H Preferred Stock and the corresponding 6,000,000 depositary shares on December 15, 2026. Depositary shares will be redeemed at $25.00 each, and the redemption price excludes the regular quarterly dividend, which is payable separately on the same date to holders of record on November 30, 2026.
Redemption date: December 15, 2026, covering 6,000 preferred shares and 6,000,000 depositary shares.
Redemption price: $25.00 per depositary share, not including the declared quarterly dividend.
Quarterly dividend: $0.328125 per depositary share, payable December 15, 2026 to holders of record as of November 30, 2026.
Redemption agent: Broadridge Corporate Issuer Solutions, LLC; shares are held through DTC.
Gogo and its subsidiary GIH signed a third amendment to their 2021 credit agreement, converting $544.4 million of term loans into new 2026 Extended Term Loans that mature October 31, 2030. The amendment requires $75 million of prepayments through December 31, 2027 and sets a higher interest margin of 5.75% over SOFR, so shareholders gain more time on debt maturities but pay more in interest and face required debt repayments.
2026 Extended Term Loans of $544.4 million mature October 31, 2030; Initial Term Loans of $33.4 million mature April 30, 2028
Required prepayments: $25.0 million on the November 6, 2026 closing date, $30.0 million by December 31, 2026, and $20.0 million by December 31, 2027
Interest at SOFR plus 5.75% or an alternate base rate plus 4.75%; quarterly amortization begins March 31, 2027
Amendment adds certain foreign subsidiaries as guarantors and grants additional collateral on a pari passu basis with the HPS Credit Agreement
Health In Tech, Inc. issued a second promissory note to investor YA II PN, Ltd. on November 2, 2026, with a principal amount of $3.0 million, which provided gross proceeds of $2.85 million after a 5% purchase price discount. The notes are convertible into Class A common stock at a fixed price of $1.5735 per share and can be converted into shares that could dilute existing holders, with an Exchange Cap of 13,100,378 shares that the company is seeking stockholder approval to exceed at its November 10, 2026 annual meeting.
Second promissory note issued November 2, 2026: $3.0 million principal, $2.85 million gross proceeds after 5% discount
Notes mature February 18, 2028, bear 8.75% annual interest (18% after certain defaults), and carry a 4% payment premium unless paid via stock sale proceeds
Conversion price fixed at $1.5735 per share with a floor price of $0.204; Exchange Cap is 13,100,378 shares, about 19.99% of outstanding Class A and Class B common stock
Company seeks stockholder approval to issue shares above the Exchange Cap at its annual meeting on November 10, 2026
Delta Air Lines completed a public offering of $500 million in 5.500% notes maturing November 6, 2029, on November 6, 2026. The company said it will use part of the proceeds to repay about $391 million of Payroll Support Program loan borrowings, about $70 million of aircraft-secured equipment notes, and, with cash on hand, about $39 million of pass through certificates, with any remainder for general corporate purposes. The filing adds new unsecured debt to the balance sheet while reducing several existing obligations.
Notes: $500 million aggregate principal, 5.500% coupon, maturing November 6, 2029
Interest paid semi-annually on May 6 and November 6, starting May 6, 2027
Proceeds to repay about $391 million Payroll Support Program loan, about $70 million equipment notes, and about $39 million pass through certificates
American Healthcare REIT entered into a new at-the-market equity sales agreement allowing it to sell up to $1.75 billion of common stock through a group of sales agents and forward purchasers. The company terminated its prior program, which had about $170 million left unsold, and says it will use any net proceeds for general corporate purposes, which may include future investments.
Agreement allows sales of common stock with an aggregate gross sales price of up to $1,750,000,000, replacing the prior program dated February 27, 2026.
About $170,134,000 remained unsold under the prior sales agreement when it was terminated.
Agents may receive a commission of up to 2.0% of gross sales price; shares are sold under a shelf registration statement on Form S-3 dated August 12, 2024.
Proceeds would go to the Operating Partnership for general corporate purposes, which may include potential future investments.
Silgan signed a consent to its credit agreement with Wells Fargo as administrative agent, letting lenders designate a new subsidiary, Silgan Metal Packaging LLC, as an unrestricted subsidiary. The change supports the planned contribution of several container and closure businesses to that entity under the October 17, 2026 Transaction Agreement. The filing gives no financial results or deal value, so the near-term effect on shareholders is not quantified here.
Consent to Amended and Restated Credit Agreement dated November 6, 2026, with Wells Fargo Bank, National Association, as Administrative Agent
Silgan Metal Packaging LLC (MetalCo) to be designated an Unrestricted Subsidiary, releasing it as a guarantor under the credit agreement
Business Contribution tied to the Transaction Agreement dated October 17, 2026 with A-VL Holdco, LP
If the MetalCo Transactions do not close, MetalCo and its subsidiaries will cease to be Unrestricted Subsidiaries
Profusa, Inc. entered into Amendment No. 4 to its Note Modification and Conversion Agreement with holder NorthView Sponsor I LLC on November 5, 2026. The amendment sets a $0.20 floor on the conversion price for the note, which has an original principal amount of up to $2,500,000. The change could result in a larger number of shares being issued to the holder on conversion, which may dilute existing shareholders.
Amendment No. 4 dated November 5, 2026 sets conversion price at the greater of $0.20 Floor Price or the prior trading day's Nasdaq closing price
Conversion shares are calculated as principal multiplied by 122%, divided by the conversion price, unchanged by the amendment
The prior Amendment No. 3 of August 12, 2026 set the conversion price at the greater of $4.28 or the prior trading day's closing price
Original note principal amount of up to $2,500,000, with the agreement first entered April 24, 2026
Energy Transfer LP priced $2.7 billion of senior notes in three equal $900 million tranches, due 2032, 2037 and 2057, with coupons of 5.450%, 5.900% and 6.550%. The offering is expected to settle on November 20, 2026, and the net proceeds of about $2.68 billion (before offering expenses) are intended to refinance existing debt, including commercial paper and revolving credit facility borrowings, and for general partnership purposes.
Three $900 million tranches: 5.450% notes due 2032, 5.900% notes due 2037 and 6.550% notes due 2057.
Prices to the public were 99.972%, 99.719% and 99.862% of face value, respectively.
Expected settlement date is November 20, 2026, subject to customary closing conditions.
Net proceeds of about $2.68 billion will refinance existing indebtedness and fund general partnership purposes; several underwriters' affiliates are lenders under the revolving credit facility and may receive a share of the repayment.
Enova International said subsidiary OnDeck Asset Securitization IV, LLC intends to offer $500,251,000 of Series 2026-2 fixed rate asset-backed notes in a private securitization backed by small business loans originated or purchased by its subsidiary ODK Capital, LLC. Closing is anticipated on or about November 13, 2026, subject to market and customary conditions, so the offering may not be completed as contemplated or at all. The notes will not be obligations of or guaranteed by Enova or OnDeck, and OnDeck expects to use substantially all proceeds for loan purchases from affiliates and general corporate purposes.
Four classes total $500,251,000: Class A $190,095,000 at 5.81%, Class B $118,744,000 at 6.15%, Class C $100,050,000 at 6.73%, Class D $91,362,000 at 8.57%.
Anticipated Kroll Bond Rating Agency ratings range from AA (sf) for Class A to BB- (sf) for Class D.
Notes are offered only to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S, and are not registered under the Securities Act.
Legal final payment date is December 19, 2033; the company announced the offering on November 3, 2026.
ACRES Commercial Realty Corp. entered into a Seventh Amendment to its Master Repurchase and Securities Contract Agreement with Morgan Stanley Mortgage Capital Holdings, which extends the agreement to November 2027 and modifies certain financial covenants in the related guaranty. The filing describes a routine financing amendment and does not disclose a borrowing amount, pricing, or fee figures beyond a reference to an unspecified Extension Fee.
Amendment dated November 2, 2026 extends the Morgan Stanley agreement to November 2027.
Company, as guarantor, agreed to amend certain financial covenants in its guaranty to Morgan Stanley.
Subsidiary ACRES Real Estate SPE 10, LLC is the seller; payment of an Extension Fee was due on or before November 3, 2026, amount not stated in the filing.
MediaCo Holding entered a Third Amendment to its First Lien Term Loan Credit Agreement, moving the maturity of its Delayed Draw Term Loans from October 31, 2026 to the earliest of November 30, 2026 or certain acceleration or debt-related triggers. The lender agent acknowledged that defaults or events of default have occurred and are continuing, and all parties reserved their rights, signaling significant financial stress for shareholders.
Delayed Draw Term Loan maturity extended from October 31, 2026 to no later than November 30, 2026
Agent acknowledged that certain defaults or events of default have occurred and are continuing
Agent and lenders reserved all rights and remedies under the Credit Agreement
Company released the agent and lenders from known claims arising on or before the amendment date
Zenas BioPharma filed a new prospectus supplement for an at-the-market offering of up to $200 million in common stock through Jefferies LLC, and ended the earlier program, under which it had sold about $153.2 million of shares with about $46.8 million unsold. The filing is a routine share-sale mechanism, and any sales would dilute existing shareholders, though the filing does not state whether or when any shares will be sold.
New prospectus supplement filed November 6, 2026, for up to $200,000,000 of common stock under the October 8, 2025 Sales Agreement with Jefferies LLC
Prior program terminated: about $153.2 million sold and about $46.8 million unsold at filing date
Shares to be offered under the existing Form S-3ASR registration statement, which became automatically effective upon filing
Ropes & Gray LLP legal opinion filed as Exhibit 5.1
NB Bancorp, Inc., the holding company of Needham Bank, issued $100 million of 7.50% fixed-to-floating subordinated notes due 2036 to institutional investors on November 6, 2026, at 100% of principal. The company estimates net proceeds of approximately $98,265,004.75 and plans to use them for general corporate purposes, including at least $30 million to increase the bank's Tier 1 capital, and the notes are intended to count as Tier 2 capital.
$100 million principal, maturing November 15, 2036, issued at 100% of principal in a private placement
Fixed rate of 7.50% until November 15, 2031, then resets quarterly to three-month SOFR plus 305 basis points
Estimated net proceeds of approximately $98,265,004.75; at least $30 million to be contributed to Needham Bank
Notes rated BBB- by Kroll Bond Rating Agency; Piper Sandler & Co. was sole placement agent
GATX Corporation agreed under an underwriting agreement dated November 2, 2026 to sell $300 million of 5.950% Senior Notes due 2036, and issued the notes to the underwriters on November 6, 2026. The filing describes a debt issuance rather than a change in operations, so its main significance for shareholders is the added long-term borrowing.
Principal amount: $300 million of 5.950% Senior Notes due 2036
Underwriting agreement dated November 2, 2026, with BofA Securities, Citigroup Global Markets and Morgan Stanley & Co. as representatives
Notes issued and delivered to underwriters against payment on November 6, 2026
Sold under shelf registration statement on Form S-3 (Registration No. 333-286436)
aTyr Pharma filed a prospectus supplement allowing it to sell common stock worth up to $79,994,251 from time to time under an existing open market sale agreement with Jefferies LLC. The filing sets up potential share issuance that could dilute existing shareholders, though the filing does not state how much stock has been or will be sold.
Maximum aggregate offering price of up to $79,994,251 under the Sales Agreement with Jefferies LLC, dated April 22, 2022, as amended December 23, 2024
Offering is made under Form S-3 shelf registration (File No. 333-289360), filed August 7, 2025 and declared effective August 18, 2025
Cooley LLP legal opinion on the legality of the shares filed as Exhibit 5.1
NextNRG, Inc. closed a debt exchange on November 3, 2026, in which CEO Michael D. Farkas exchanged $7,000,000 of notes, interest and guarantee fees for 7,000 shares of newly designated Series D Convertible Voting Preferred Stock. The company says this reduces indebtedness and supports its efforts to meet Nasdaq's $2.5 million stockholders' equity requirement, but the filing states that the exchange alone does not satisfy that requirement. The Series D shares accrue an 18% annual cumulative dividend, are convertible into common stock at an initial $2.20 price, and carry voting rights, which may dilute common shareholders.
Exchange covered $3,629,924 in note principal, $2,749,169 in accrued interest and $620,907 in guarantee fees, with the closing on November 3, 2026
7,000 Series D shares carry an initial stated value of $1,000 per share, with a cumulative dividend of 18% a year compounding monthly
Initial conversion price is $2.20 per share; conversion and voting are capped at 1,684,224 shares, or 9.99%, until the Cap Release Date
Nasdaq requires at least $2.5 million in stockholders' equity; the exchange alone does not satisfy that requirement, and the company awaits a Nasdaq Hearings Panel decision
Public Storage Operating Company, a subsidiary of Public Storage, completed a $500 million offering of 5.600% Senior Notes due November 15, 2036, guaranteed by Public Storage. The filing describes new long-term unsecured debt with covenants limiting secured and unsecured borrowing and requiring unencumbered assets of at least 125% of unsecured indebtedness.
Principal amount of $500 million; interest at 5.600% per year, accruing from November 6, 2026
Interest payable semi-annually on May 15 and November 15, starting May 15, 2027; maturity November 15, 2036
Notes are unsecured and rank equally with existing and future unsecured debt of the issuer; redeemable at a make-whole price, or at 100% of principal from August 15, 2036
Offering made under a Form S-3 shelf registration; prospectus supplement dated October 29, 2026
Janus Living, Inc. closed a registered underwritten public offering of 30,187,500 Class A-1 common shares on November 6, 2026, including the underwriters' full exercise of their option to buy 3,937,500 additional shares. The filing does not state the offering price or the proceeds, and the issuance adds shares that will dilute existing holders' ownership.
Offering closed November 6, 2026 with 30,187,500 Class A-1 common shares, $0.01 par value
Underwriters exercised their option in full for 3,937,500 additional shares
Underwriting Agreement dated November 4, 2026 with BofA Securities, J.P. Morgan, Wells Fargo and Goldman Sachs as representatives
Repligen closed private exchange and subscription transactions on November 6, 2026, issuing $1.0 billion of 0.25% Convertible Senior Notes due 2031. About $541.4 million of the new notes swapped out $456.8 million of its 1.00% notes due 2028, and $458.6 million was sold for cash. The filing shows the company took on new debt with a lower coupon and a conversion price about 20% above the October 29, 2026 closing price, which could mean future share dilution if holders convert.
Issued $1.0 billion of 0.25% Convertible Senior Notes due November 1, 2031, with interest paid semi-annually starting May 1, 2027
Exchanged $456.8 million of 1.00% 2028 notes for $541.4 million of new notes; $143.2 million of 2028 notes remain outstanding
Initial conversion price of about $226.37 per share, roughly 20% above the $188.64 closing price on October 29, 2026
Up to 5,301,100 shares of common stock may be issued on conversion, including make-whole additional shares
PowerCompute entered into a Fourth Amendment to a Secured Promissory Note with Brown Family Enterprises LLC, effective October 31, 2026, extending the maturity of a $1,250,000 loan from December 31, 2026 to December 31, 2027. The filing describes a debt maturity extension only and does not state any change to the loan amount or other terms, so it defers repayment pressure by one year.
Loan principal amount: $1,250,000 from Brown Family Enterprises LLC
Maturity date extended from December 31, 2026 to December 31, 2027
Amendment dated October 31, 2026, agreement entered November 2, 2026
60 Degrees Pharmaceuticals agreed on November 5, 2026, to offer inducement letters to holders of existing warrants, who would exercise 584,492 shares at a reduced $0.90 per share. The company expects gross proceeds of $526,042.80 before fees, and in exchange will issue new unregistered warrants for up to 1,168,984 shares, which could add to share count and dilute existing shareholders.
Holders would exercise existing warrants for 584,492 shares at a reduced $0.90 per share, with expected gross proceeds of $526,042.80 before fees.
New warrants for up to 1,168,984 shares, equal to 200% of the exercised shares, carry a $0.90 exercise price and cannot be exercised before stockholder approval.
H.C. Wainwright & Co. is placement agent, receiving a 7.5% cash fee, a 1.0% management fee and placement agent warrants for 43,837 shares.
Closing is expected on or about November 9, 2026, subject to customary conditions.
On November 5, 2026, EVERTEC's subsidiary Evertec Group, LLC refinanced its $387.8 million Term A loan and replaced its revolving facility under a seventh amendment to its credit agreement with Truist Bank as agent. Both facilities now mature on November 5, 2031, and revolving commitments rose from $200.0 million to $300.0 million. The company said pricing fell 25 basis points, and it paid the transaction costs with cash on hand.
Term A facility of $387.8 million refinanced through a cashless roll and now matures November 5, 2031, subject to a springing maturity tied to Term B loans.
Revolving commitments increased from $200.0 million to $300.0 million, with an additional $100 million incremental commitment fungible with the existing revolver.
Interest margins range from 1.25% to 2.25% for SOFR term loans and 0.25% to 1.25% for alternate base rate loans, based on the Total Net Leverage Ratio.
Term B loans maturing October 30, 2030 had $875 million outstanding as of November 6, 2026, and the filing says their terms are not affected.
TKO Group Holdings priced a $1.0 billion offering of 6.500% Senior Secured Notes due 2031, issued by its indirect subsidiary TKO Worldwide Holdings, LLC. The company said net proceeds may fund general corporate purposes, including distributions to parent entities to fund share repurchases under its existing program. The offering adds $1.0 billion of secured debt, which shareholders may weigh against the planned buybacks.
Pricing announced November 5, 2026: $1.0 billion aggregate principal amount of 6.500% Senior Secured Notes due 2031
Issuer is indirect subsidiary TKO Worldwide Holdings, LLC; notes guaranteed by TKO Guarantor, LLC and certain subsidiaries
Proceeds may fund share repurchases under TKO's previously announced program, plus fees and expenses
Closing expected on or about November 13, 2026, subject to customary conditions
Parabolic Technologies, Inc. (Nasdaq: PARA) closed a $13.5 million underwritten public offering on November 5, 2026, selling units that each include one share or a pre-funded warrant plus two warrants. The filing says net proceeds were approximately $5.512 million, and the warrants include exercise-price resets that can increase the number of shares issuable, which could dilute existing shareholders.
Gross proceeds of about $13.5 million from 4,963,235 units priced at $2.72 each, with net proceeds of about $5.512 million after offering expenses
Each unit includes two warrants with an initial exercise price of $6.80 per share, for up to 9,926,470 warrant shares
Warrants reset on the fifth and tenth trading days after issuance to the lower of the then-current exercise price and 80% of the lowest VWAP in the measurement period, subject to floor prices, and holders keep additional shares from resets
Aegis Capital Corp. holds a 45-day over-allotment option, and the Underwriter exercised it for 360,000 warrants on November 5, 2026
Annovis Bio agreed on November 5, 2026 to sell 19,000,000 shares of common stock (or pre-funded warrants in lieu of shares) with accompanying warrants, with expected gross proceeds of approximately $21.0 million before underwriting discounts and expenses. The offering adds shares and warrants that could dilute existing shareholders, while the company plans to use the proceeds for clinical development of buntanetap and working capital.
Offering of 19,000,000 shares plus pre-funded warrants for up to 2,000,000 shares, with accompanying warrants for up to 21,000,000 shares, priced at $1.00 per share and accompanying warrant
Accompanying warrants are exercisable at $1.00 per share and expire five years after issuance
One of the company's directors is buying 5,000,000 shares and accompanying warrants for $5,000,000
Offering is expected to close on or about November 6, 2026, with Canaccord Genuity LLC as underwriter
On November 2, 2026, Public Policy Holding Company, Inc. (PPHC) entered a $105 million senior secured credit facility with Bank of America, N.A. as administrative agent, and used it to repay and terminate its existing credit agreement. The facility consists of a $65 million term loan and a $40 million revolving credit facility, maturing November 2, 2031, and the company says proceeds will also fund the Reevemark acquisition and working capital.
Facility of $105 million: a $65 million term loan and a $40 million revolving credit facility, maturing November 2, 2031
$65 million was borrowed under the term loan at closing
Interest is SOFR plus 185 to 230 basis points, set by net leverage; the company plans syndication to $150 million, expected to close January 2027 on a best-efforts basis
Existing credit agreement dated February 28, 2023 was repaid and terminated
CBRE Services, a wholly-owned subsidiary of CBRE Group, completed a $1 billion offering of senior notes in two $500 million tranches due 2032 and 2037. The Company intends to use the proceeds for general corporate purposes, including repaying commercial paper borrowings and funding the pending acquisition of Onnec Group Limited, which adds debt that shareholders will need to service.
$500 million of 5.650% Senior Notes due January 15, 2032, with semi-annual interest beginning January 15, 2027
$500 million of 5.900% Senior Notes due January 15, 2037, with semi-annual interest beginning January 15, 2027
Notes are fully and unconditionally guaranteed on a senior unsecured basis by CBRE Group, Inc.
Proceeds intended for commercial paper repayment and the pending acquisition of Onnec Group Limited
Meta Platforms completed a $15.0 billion offering of five U.S. dollar senior note series maturing from 2031 to 2056, with fixed rates from 5.850% to 7.500%. Underwriters also exercised in full their option to buy 6,000,000 additional Class A common shares from an offering priced in late October 2026, with forward sale agreements covering those shares. The filing does not state how the proceeds will be used, so the added debt and share sales are the main points for shareholders to weigh.
Five senior note series: $3.25 billion due 2031, $3.25 billion due 2033, $4.0 billion due 2036, $1.75 billion due 2046 and $2.75 billion due 2056
Notes were issued under an indenture dated August 9, 2022 with U.S. Bank Trust Company, National Association, as trustee, and a sixth supplemental indenture dated November 5, 2026
Underwriters exercised their option in full on November 4, 2026 for 6,000,000 additional Class A common shares, with additional forward sale agreements on similar terms
Underwriting agreement dated November 3, 2026 with Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC as representatives
CVR Energy agreed to sell 10,515,248 common shares at $47.55 each, with net proceeds of about $490.0 million before offering expenses, closing November 5, 2026. The company plans to use the proceeds with cash on hand and other financing to fund its acquisition of the St. Paul Park and Mandan refineries from Marathon Petroleum subsidiaries, redeem its 5.750% Senior Notes due 2028, and pay related fees.
Offering: 10,515,248 shares at $47.55 per share, with a 30-day option for up to 1,577,287 additional shares
Net proceeds of approximately $490.0 million; offering closed November 5, 2026
Proceeds to fund the St. Paul Park and Mandan refinery acquisition and redeem 2028 Notes; if the acquisition does not close, proceeds go to general corporate purposes
Selling stockholder IEP Energy Holding LLC is not included in the priced offering; the company receives no proceeds from its shares
Otis Worldwide issued $500 million of 5.825% notes maturing November 5, 2036, with estimated net proceeds of about $495.3 million. The company plans to use the proceeds with cash on hand to repay its 2.293% notes due April 5, 2027, which had $500 million outstanding as of September 30, 2026. This is a routine debt refinancing that replaces near-term maturing debt with longer-dated debt at a higher stated interest rate.
Notes: $500 million principal, 5.825% annual interest, maturing November 5, 2036; interest payable May 5 and November 5 starting May 5, 2027
Estimated net proceeds of about $495.3 million, to repay 2.293% notes due April 5, 2027 ($500 million outstanding at September 30, 2026)
Notes are unsecured and rank equally with existing unsecured debt; make-whole redemption before August 5, 2036; 101% change of control put
Spruce Power subsidiaries amended their KeyBank credit agreement on October 30, 2026, changing covenant terms tied to a refinancing and requiring new deliverables by November 9, 2026. The same day, subsidiaries signed a non-binding term sheet with a financial institution for a funded debt facility to refinance the SP1, SP2 and SP3 facilities, but the filing states the terms remain indicative and subject to change. The filing also warns that failure to complete a refinancing by January 30, 2027 could have serious consequences, including going-concern risk.
October 30, 2026: subsidiaries amended the Second KeyBank Credit Agreement and entered a term sheet with a financial institution
By November 9, 2026: company must deliver a long-term financial model assuming refinancing of Senior Loan Obligations, and SP4 HoldCo and SP5 HoldCo must execute agreements for the SP4/SP5 Collateral Addition covenant
The proposed Refinancing Facility would refinance the SP1, SP2 and SP3 facilities; the filing cites a January 30, 2027 refinancing risk date
Xometry issued a notice to redeem all approximately $85.0 million of its 1.00% Convertible Senior Notes due 2027, with redemption set for November 20, 2026, at 100% of principal plus accrued interest. Holders may still convert the notes into Class A common stock until 5:00 p.m. New York City time on November 19, 2026, and the filing says conversions after the notice will settle in physical shares. The filing is a debt-management step and gives no results or guidance figures.
Notes to be redeemed: all approximately $85.0 million aggregate principal of 1.00% Convertible Senior Notes due 2027
Redemption date: November 20, 2026, at 100% of principal plus accrued and unpaid interest from August 1, 2026
Conversion deadline: 5:00 p.m. New York City time on November 19, 2026; each $1,000 converts into 17.8213 shares, plus 0.0018 additional shares for conversions before the deadline
Live Oak Bancshares agreed on November 4, 2026 to sell 4,000,000 depositary shares, each representing a 1/40th interest in its 8.750% Series B non-cumulative perpetual preferred stock, at a $25 liquidation value per depositary share. The company expects the offering to close on or about November 12, 2026, and says the net proceeds will fund general corporate purposes, including balance sheet growth at Live Oak Banking Company and its capital position.
Underwriters are Morgan Stanley & Co. LLC, Keefe, Bruyette & Woods, RBC Capital Markets and UBS; the underwriters have a 30-day option for up to 600,000 additional depositary shares.
Dividends are 8.750% per annum, payable quarterly when declared by the board, beginning December 15, 2026.
The company may redeem the Series B preferred stock on or after December 15, 2031, or after a regulatory capital treatment event, at $1,000 per share ($25 per depositary share).
Live Oak intends to list the depositary shares on the NYSE under the symbol LOB/PB.
Xcel Energy issued $2.5 billion of 2.625% convertible senior notes due December 15, 2027, including $300 million from the initial purchasers' option. The notes are convertible into Xcel common stock at an initial conversion price of about $87.26 per share, and conversions can be settled in cash, shares, or a mix. Because the notes are convertible, they could add up to 31,513,750 shares of common stock to the share count if holders convert at the maximum rate.
Issued $2,500,000,000 of 2.625% Convertible Senior Notes due December 15, 2027, dated November 5, 2026
Initial conversion rate of 11.4596 shares per $1,000 principal, or about $87.26 per share
Up to 31,513,750 shares may be issued on conversion at the initial maximum conversion rate of 12.6055 shares per $1,000
Notes cannot be redeemed by Xcel Energy before maturity and carry no sinking fund
Enova International priced a private offering of $600 million in senior notes due 2031 at par, bearing 8.750% annual interest, with closing expected November 20, 2026. The company plans to use the proceeds to redeem all of its 11.25% senior notes due 2028 on December 15, 2026, pay offering fees, and repay part of its revolving credit facility borrowings, which refinances higher-rate debt for shareholders to watch.
Offering size: $600 million aggregate principal amount of senior notes due 2031, priced at 100.000% of principal
Interest rate: 8.750% per annum; notes are senior unsecured and guaranteed by domestic subsidiaries
Expected closing: November 20, 2026, subject to customary conditions
Use of proceeds: redeem all 11.25% senior notes due 2028 on December 15, 2026, and repay part of revolver borrowings
HCA Inc., a wholly owned subsidiary of HCA Healthcare, completed on November 5, 2026 a public offering of $6.5 billion of senior unsecured notes in seven series maturing from 2028 to 2056, fully guaranteed by HCA Healthcare. The filing does not state how the proceeds will be used, but the offering adds $6.5 billion of debt obligations for the company.
Seven series totaling $6.5 billion; the largest is $1.5 billion of 6.000% senior notes due November 15, 2036.
Fixed-rate coupons range from 5.200% to 6.500%, and $300 million of floating-rate notes mature November 3, 2028.
Underwriting agreement dated November 2, 2026 with Mizuho Securities USA LLC, Barclays Capital Inc., BofA Securities, Inc. and Wells Fargo Securities, LLC as representatives.
Holders can require repurchase at 101% of principal only upon both a qualifying ratings downgrade and a change of control.
TD SYNNEX entered into a $1,750 million senior unsecured term loan with Bank of America as administrative agent, dated November 2, 2026. Part of the proceeds repaid in full an existing $750 million term loan that would have matured September 1, 2027, and the rest will fund general corporate purposes, including acquisitions.
New term loan: $1,750 million, maturing November 2, 2029, with no scheduled amortization before maturity
Interest set at SOFR plus a margin of 1.00% to 1.625%, based on TD SYNNEX's public debt rating
Repaid in full the $750 million term loan that would have matured September 1, 2027
Financial covenants require a maximum funded debt to EBITDA ratio of 4.00 to 1.00 and a minimum EBITDA to interest charges ratio of 3.00 to 1.00
Aeries Technology disclosed a settlement agreement dated October 30, 2026, with Sea Otter Trading, LLC over obligations under a forward purchase agreement. The company agreed to pay $911,461 through an escrow arrangement in exchange for the return of 145,183 Class A ordinary shares held as collateral, and mutual general releases will take effect once the share transfer and payment are completed. The filing does not disclose the company's financial results, and it replaces the earlier letter agreement terms that had been disclosed August 3, 2026.
Settlement agreement dated October 30, 2026, with Sea Otter Trading, LLC
Company to pay $911,461 through escrow to recover 145,183 collateral Class A ordinary shares
Mutual general releases and termination of the Letter Agreement take effect upon completion of the share transfer and payment
Fate Therapeutics entered a Sales Agreement with Leerink Partners for an at-the-market program allowing it to sell up to $100 million of common stock at its discretion, and terminated its earlier $100 million program with Jefferies. The company has already sold 2,801,602 shares for $8.0 million under the Jefferies program. The new program could add shares outstanding and dilute existing shareholders if the company chooses to sell.
Leerink Partners may sell up to $100,000,000 of common stock; the company pays a commission of up to 3.0% of gross proceeds.
The Jefferies program was terminated on November 5, 2026, with no termination penalties, after sales of 2,801,602 shares for $8.0 million.
The existing Form S-3 expires November 27, 2026; the company plans to file a new registration statement, and may sell under the existing one until the earlier of the new registration's effectiveness and May 26, 2027.
Alphabet closed an underwritten public offering of €6 billion in euro-denominated senior notes on November 5, 2026, issued under an indenture dated February 12, 2016. The notes come in seven tranches maturing between 2028 and 2045, which adds to the company's long-term debt.
Total offering of €6 billion across seven tranches, maturing 2028 to 2045
Largest tranches are €1.25 billion of 4.050% notes due 2030 and €1 billion of 5.250% notes due 2045
Issued under a registration statement on Form S-3 and an indenture with The Bank of New York Mellon Trust Company, N.A., as trustee
Brixmor's operating partnership signed a $400 million delayed-draw term loan facility, undrawn as of November 5, 2026, and amended its existing revolving credit and term loan agreements to lower borrowing rates and facility fees. The filing describes financing terms rather than a reported change in earnings, and the facility is not yet drawn.
$400 million delayed-draw term loan facility with Wells Fargo, drawable within six months and maturing February 15, 2031
Revolver amendment with JPMorgan Chase lowers term SOFR margins to 0.65% to 1.35% and facility fees to 0.10% to 0.30%
Term loan amendment lowers term SOFR margins to 0.70% to 1.55%, with pricing tied to credit rating
Aimei Health Technology Co., Ltd. deposited $34,330.96 into its trust account to extend the deadline to complete its initial business combination by one month, from November 6, 2026 to December 6, 2026. The company funded the payment with an unsecured, non-interest-bearing promissory note to Aimei Investment Ltd, which becomes due only at the business combination, so the extension adds to the company's obligations for public shareholders.
Extension Payment of $34,330.96 is the lesser of $80,000 or $0.033 per outstanding public share for each monthly extension.
Termination date moves from November 6, 2026 to December 6, 2026; the filing describes this as the twenty-fourth extension.
Promissory note dated November 5, 2026, issued to Aimei Investment Ltd, is convertible at the payee's option into private units at $10.00 per unit.
On October 29, 2026, Cycurion entered into agreements giving Obsidian Associates, LLC and M2B Funding Corp. a limited right to exchange their Series H Convertible Preferred Stock, plus accrued and unpaid dividends, for common stock at $2.70 per share, subject to a possible Nasdaq Minimum Price adjustment. Upon exchange, the preferred shares are cancelled and the holders receive only common stockholder rights on the new shares, so existing common shareholders may face dilution, though the filing does not state the number of common shares to be issued.
Holders: Obsidian Associates, LLC (618.75 Series H shares) and M2B Funding Corp. (952.70 Series H shares), plus accrued dividends
Exchange price of $2.70 per common share, subject to adjustment to the Nasdaq Minimum Price if applicable
Exchange window opens after the Company files a Listing of Additional Shares notice with Nasdaq and publicly discloses the transactions
Agreements include a 4.99% beneficial ownership limit and a resale limit of 5.0% of average daily trading volume over the prior ten trading days
Prospect Capital Corporation closed a $300 million offering of 8.95% senior unsecured notes due October 31, 2031 on November 5, 2026, issued under a registered direct offering. The Company expects net proceeds of about $283.4 million, mainly to refinance existing debt, including repaying its 3.364% Notes due 2026 and/or revolver borrowings.
Principal: $300 million of 8.95% Notes due October 31, 2031, with interest paid semi-annually on April 30 and October 31, starting April 30, 2027
Expected net proceeds: approximately $283.4 million after estimated offering expenses
Use of proceeds: primarily refinancing, including repayment of the 3.364% Notes due 2026 and/or revolving credit facility borrowings
Optional redemption at par plus a make-whole premium before April 30, 2029; holders may require repurchase at par plus accrued interest upon a Change of Control Repurchase Event
L3Harris closed the sale of $1.0 billion of senior notes on November 5, 2026, split into $500 million due 2029 at 5.200% and $500 million due 2032 at 5.400%. The company plans to use the proceeds for general corporate purposes, including repaying $550 million of 3.85% notes due December 15, 2026 and helping fund part of the $1,250 million 5.40% notes due January 15, 2027.
$1.0 billion total: $500 million of 5.200% notes due 2029 and $500 million of 5.400% notes due 2032
Proceeds earmarked for the $550 million 3.85% notes maturing December 15, 2026
Proceeds, with cash on hand, to partly fund the $1,250 million 5.40% notes maturing January 15, 2027
Kartoon Studios said its sponsored subsidiary, Kartoon Studios Acquisition Corp. (KSAC), filed a Form S-1 registration statement for a proposed $300 million initial public offering of units. The registration statement has not yet become effective, and the units cannot be sold until it does. KSAC intends to pursue media and entertainment business combinations, and the company said there is no assurance the filing will result in any transaction.
Proposed offering of 30,000,000 units at $10.00 per unit, for gross proceeds of $300.0 million, plus an underwriter option for up to an additional 15% of units
Each unit consists of one Class A ordinary share and one redeemable warrant; KSAC intends to list the units on the New York Stock Exchange under the symbol 'KACQ U'
E.F. Hutton & Co. is sole underwriter and book-running manager; Kartoon owns 100% of the sponsor, Toon Acquisition LLC
Andy Heyward, Brian Parisi and Michael Jaffa will lead KSAC, and the filing was announced on November 5, 2026
HCW Biologics entered into a notes purchase agreement with Streeterville Capital on November 3, 2026, and closed the financing on November 4, 2026. The company received $3.0 million at closing, with a further $7.0 million held in a controlled account subject to conditions, and says it will use the proceeds for clinical development, business development and general corporate purposes. The notes are secured and carry lender redemption rights, default triggers and a 10% prepayment premium, which shareholders should weigh against the added funding.
$3.0 million received at closing on November 4, 2026, after $30,000 in transaction costs; a further $7.0 million is deposited in a controlled account subject to conditions
Promissory Note A-1 of $3.2 million includes a $240,000 original issue discount; Note B of $7.0 million carries no discount; both are due in 24 months, at 8% and 5% interest per annum
Beginning six months after closing, the lender may redeem up to $125,000 per calendar month on the A-1 Note; the notes are secured by a controlled account, a subsidiary guaranty and a pledge of subsidiary membership interests
Maxim Group LLC, the placement agent, is to receive a cash fee of 7.0% of gross proceeds
Avalo Therapeutics entered an at-the-market sales agreement with Jefferies LLC that lets it sell up to $200 million of common stock over time at its discretion, with a commission of up to 3.0% of gross proceeds. The same day, the company ended its prior at-the-market agreement with TD Cowen, effective immediately, so new share sales can only occur under the Jefferies arrangement. New share sales would add to the outstanding shares and could dilute existing shareholders.
Jefferies sales agreement covers up to $200,000,000 in aggregate offering price under a prospectus supplement dated November 5, 2026.
Company pays Jefferies a commission of up to 3.0% of gross proceeds from any shares sold.
The company is not obligated to sell any shares, and it may suspend or terminate the offering.
TD Cowen sales agreement, dated June 5, 2025, was terminated effective November 5, 2026.
America's Car-Mart amended its Credit and Guaranty Agreement with Silver Point Finance, LLC, as agent, and its lenders, and agreed to further extend the Scheduled Termination Date and temporary relief on minimum liquidity and Collateral Coverage Ratio requirements through November 9, 2026. The filing shows the company needed repeated short extensions of its credit terms, which signals ongoing pressure on its lending arrangements for shareholders.
First Amendment and Limited Waiver to the Credit Agreement dated October 30, 2025, with Silver Point Finance, LLC as Administrative Agent and Collateral Agent
Scheduled Termination Date previously extended through November 4, 2026, and now extended again through November 9, 2026
Temporary relief on minimum liquidity thresholds and minimum Collateral Coverage Ratio also extended through November 9, 2026
3D Systems signed a Controlled Equity Offering sales agreement with Cantor Fitzgerald & Co. allowing it to sell common stock worth up to $42.5 million through an at-the-market program, at its discretion. The filing states the company is not obligated to sell any shares, so sales would dilute existing holders only if and when they occur.
Agreement dated November 5, 2026 covers shares with an aggregate offering price of up to $42,500,000
Cantor Fitzgerald will be paid a commission of up to 3.0% of the gross sales price per share sold
Shares will be issued under a Form S-3 shelf registration declared effective May 27, 2026
Either the company or Cantor Fitzgerald may terminate the agreement on ten business days' written notice
Dream Finders Homes said that as of 5:00 p.m. New York City time on November 4, 2026, holders had tendered 99.22% of Beazer's 7.500% notes due 2031 and 98.28% of its 8.000% notes due 2032 in an exchange for new Dream Finders notes, and it received the majority consents needed to amend the Beazer indentures. The amendments would eliminate substantially all restrictive covenants and events of default, and would bind all holders of each series once operative. The exchange offer expires November 20, 2026, with settlement expected November 23, 2026, and the filing does not include any financial results.
7.500% notes due 2031: $248,062,000 of $250,000,000 principal tendered (about 99.22%) as of November 4, 2026.
8.000% notes due 2032: $393,125,000 of $400,000,000 principal tendered (about 98.28%) as of November 4, 2026.
Early participants receive $1,000 of new Dream Finders notes, a $50 early participation premium and $1.00 in cash per $1,000 exchanged; later tenders receive $950 of new notes per $1,000.
Expiration is 5:00 p.m. New York City time on November 20, 2026; settlement is expected November 23, 2026.
3D Systems agreed on November 4, 2026 to exchange all $92,030,000 of its 5.875% convertible senior secured notes due 2030 for $85,000,000 of new 3.30% convertible notes due 2031, 13,471,138 common shares and $20,000,000 in cash. The company says the exchange would eliminate all secured debt, and it expects to close on or about November 12, 2026, subject to conditions. Shareholders face potential dilution from the new shares and the up to 32,196,963 shares that could be issued on conversion, and the company receives no cash proceeds from the exchange.
Exchange covers all $92,030,000 of 2030 Notes; holders receive $85,000,000 of 3.30% notes due April 1, 2031, 13,471,138 shares and $20,000,000 in cash
New notes carry an initial conversion price of about $3.43, a premium of about 30.0% over the $2.64 closing price on November 4, 2026
Closing expected on or about November 12, 2026; closing may be postponed to November 19 or December 4, 2026, and the agreements terminate if closing has not occurred by December 15, 2026
The company will not receive any cash proceeds from the exchange
Quoin Pharmaceuticals signed a sales agreement with Leerink Partners LLC that lets it sell American Depositary Shares from time to time through an at-the-market offering. Leerink would receive 3.0% of gross sale proceeds, and the filing does not state a dollar amount or number of shares to be sold, so the potential dilution to shareholders is not quantified.
Sales agreement with Leerink Partners LLC dated November 4, 2026; each ADS represents 35 ordinary shares.
Leerink Partners would be paid 3.0% of gross sale proceeds from ADSs sold through it.
Sales are made under Form S-3 (File No. 333-299668), declared effective November 4, 2026; the filing states no aggregate offering size.
Either party may suspend or terminate the agreement at any time upon notice.
Summit Therapeutics filed a prospectus supplement under its automatic shelf registration statement on Form S-3 and an accompanying 8-K to file a legal opinion from Baker & Hostetler LLP on the legality of the common stock issuance. The filing does not state the number of shares, the price, or the amount of proceeds, so the filing alone does not show the size or dilution effect of the offering.
Prospectus supplement filed November 4, 2026 under Form S-3 (Registration No. 333-296642)
Baker & Hostetler LLP legality opinion filed as Exhibit 5.1, with consent as Exhibit 23.1
Filing does not disclose share count, offering price, or proceeds
Olin Corporation and its subsidiary Olin Finance Company, LLC entered into Amendment No. 2 to a receivables purchase agreement with PNC Bank, National Association, on November 4, 2026. The amendment, among other things, extends the scheduled termination date to July 31, 2028, and the filing attaches the full text as Exhibit 10.1; the filing gives no financial amounts for the facility.
Agreement dated November 4, 2026, amends the Receivables Purchase Agreement dated November 20, 2024
Scheduled termination date extended to July 31, 2028
Olin Corporation acts as servicer and performance guarantor; PNC Bank, National Association is administrative agent
On November 4, 2026, WEC Energy Group entered into an equity distribution agreement allowing it to sell up to $4 billion of common stock through a group of sales agents and forward purchasers. The company expects to receive proceeds only when shares are sold and settled under forward sale agreements, and no proceeds are received from borrowed shares sold initially, so the program could dilute existing shareholders as shares are issued.
Maximum aggregate sales price under the Equity Distribution Agreement is $4 billion of common stock, $0.01 par value.
Sales agents include Barclays, BofA Securities, Citigroup, Goldman Sachs, J.P. Morgan, Morgan Stanley and Wells Fargo, among others.
Company will not initially receive proceeds from borrowed shares sold by forward sellers; proceeds come at later physical settlement.
On November 4, 2026, STERIS and its subsidiaries entered a new $1.6 billion revolving credit facility that replaces the existing credit agreement dated October 7, 2024, and a separate delayed draw term loan of up to $500 million. The term loan can be drawn only if STERIS completes its acquisition of Xodus Medical, Inc. For shareholders, the filing adds committed borrowing capacity tied to that acquisition, and the filing does not state the acquisition price or the amount that will be borrowed.
Revolving credit facility of $1,600 million matures on November 4, 2031, with an incremental increase of up to $800 million available.
Delayed draw term loan of up to $500 million can be used only after the Xodus Medical Acquisition is consummated and terminates if that deal is validly terminated or the outside date occurs.
Term loan matures five years after the acquisition closing date; no principal is due in year one, then 1.25% quarterly in years two and three and 1.875% quarterly in years four and five.
No borrowings were incurred to refinance the existing credit agreement at closing, and all term loan lenders are also lenders under the revolver.
On November 4, 2026, Kimberly-Clark settled exchange offers under which holders of Kenvue notes, assumed after its merger with Kenvue, exchanged them for new Kimberly-Clark notes with the same rates and maturities. The amendments removed substantially all restrictive covenants from the Kenvue notes still outstanding, so the financing terms for shareholders change mainly through the new Kimberly-Clark debt and the reduced protections for remaining Kenvue noteholders.
Settlement date was November 4, 2026; exchange offers expired November 2, 2026
Kimberly-Clark issued seven series of notes, with accepted principal ranging from $702,706,000 (4.850% notes due 2032) to $1,478,073,000 (5.050% notes due 2053)
Early participants received $970 principal of new notes, a $30 premium and $1.00 cash per $1,000 Kenvue notes tendered
Kimberly-Clark notes are general, unsecured senior obligations ranking equally with its existing unsecured senior debt
Applied Optoelectronics entered a new Credit Agreement on October 30, 2026, with East West Bank as administrative agent, providing $30 million in revolving commitments and $170 million in initial term loan commitments. The company terminated its prior $35 million unused-revolver facility with BOK Financial on October 29, 2026, paying a $350,000 termination fee; the new facility matures October 30, 2030 and is secured by substantially all company assets.
New Credit Agreement dated October 30, 2026: $30 million revolving commitments and $170 million initial term loan commitments
Incremental term loan commitments of up to $50 million available subject to certain conditions
Prior Loan and Security Agreement dated July 31, 2025 terminated October 29, 2026; $350,000 termination fee paid
New facility matures October 30, 2030 and is secured by substantially all company assets
On November 4, 2026, FTC Solar resumed use of its at-the-market offering program and executed common stock sales under it that day. The company had said in its September 30, 2026 quarterly report that it had no current plans to use the remaining capacity, and it says that statement no longer reflects its plans.
Sales of common stock were executed under the ATM Program on November 4, 2026, under a sales agreement dated May 1, 2025 with H.C. Wainwright & Co., LLC.
The 10-Q for the quarter ended September 30, 2026 said there were no current plans to use the remaining ATM capacity; the company now says that no longer reflects its plans.
The company says future sales depend on market conditions and that it is under no obligation to sell additional shares.
The filing states that any sales may be at prices that cause additional dilution to existing stockholders.
On October 29, 2026, PodcastOne, its majority parent LiveOne, and subsidiary guarantors entered into a Forbearance Agreement with holders of LiveOne's 11.75% senior secured convertible debentures. The lenders agreed not to exercise remedies for certain Events of Default that may have occurred, in exchange for cash payments, a fee in PodcastOne shares, and a new exit fee. The share issuance adds to the common stock outstanding, and the filing indicates the debt remains in default-related negotiations.
PodcastOne issued 275,000 common shares to the holders in a private placement as a fee for the forbearance
LiveOne must pay $1,000,000 within 30 days and $1,250,000 within 60 days of October 29, 2026
Exit fee of the greater of $1,000,000 or 1.5% of Company Sale Proceeds above $50,000,000, payable on maturity or a Company Sale
PodcastOne must file a resale registration statement within 30 days; late filing triggers payments of 2% per 30 days, up to 4%
On October 29, 2026, LiveOne and certain subsidiaries entered a Forbearance Agreement and Amendment to Debentures with holders of its 11.75% senior secured convertible debentures issued May 19, 2025. The holders agreed to forbear from exercising remedies for an existing Event of Default, but the company must make $1,000,000 and $1,250,000 payments and faces a contingent exit fee tied to a sale of PodcastOne. The filing adds new cash obligations and a default-related arrangement that shareholders should weigh.
Forbearance covers Event of Default under Section 7(a)(iii) of each debenture occurring before October 29, 2026; it ends on a Forbearance Termination Event or full payment of the obligations.
Company must pay $1,000,000 within 30 days and $1,250,000 within 60 days of the October 29, 2026 Effective Date.
November 2026 Holder Redemption Amount is deferred to December 15, 2026; redemption rights resume in December 2026.
PodcastOne issued 275,000 shares to the holders as a fee; an exit fee equal to the greater of $1,000,000 or 1.5% of PodcastOne sale proceeds above $50,000,000 applies on a PodcastOne sale.
Oracle issued 86,206,897 shares of common stock under an underwriting agreement dated November 2, 2026, with the offering closing on November 4, 2026. It also sold $10 billion of notes in five tranches maturing from 2029 to 2046, with net proceeds for general corporate purposes, which may include capital expenditures, debt repayment, acquisitions, dividends or buybacks. Shareholders face dilution from the new shares, and the filing does not state the net proceeds or how they will be allocated.
Common stock: 86,206,897 shares sold under an underwriting agreement with BofA Securities, Inc. as representative, closed November 4, 2026
Notes issued November 4, 2026: 7.000% due 2029 ($2.0 billion), 7.450% due 2031 ($1.75 billion), 7.850% due 2033 ($2.25 billion), 8.000% due 2037 ($2.5 billion), 8.650% due 2046 ($1.5 billion)
Net proceeds from both offerings will fund general corporate purposes, which may include capital expenditures, debt repayment, acquisitions and shareholder payouts
Vivakor disclosed that J.J. Astor & Co. converted $500,000 of its Fourth Note into 837,860 shares of common stock on October 29 and 30, 2026, and the company issued those shares without a Rule 144 restrictive legend. The same filing furnished three press releases on a proposed hydrogen plant at a Texas airport, an engagement of a business strategist, and a proposed $40 million acquisition of Direct Midstream, all of which remain subject to definitive agreements.
Conversion: $500,000 of the Fourth Note converted into 837,860 common shares between October 29 and October 30, 2026.
Fourth Note: issued February 27, 2026, with a $993,750 principal amount and $710,000 received before fees; the company says it is the final note outstanding with J.J. Astor.
Airport project: a nonbinding letter of intent dated October 14, 2026 covers about 12.9 acres for a proposed hydrogen plant and fueling station.
Direct Midstream: the proposed $40 million acquisition remains subject to a definitive purchase agreement.
Middleby and its subsidiary Middleby Marshall entered a new five-year Ninth Amended and Restated Credit Agreement with Bank of America as administrative agent, providing a $2.0 billion multicurrency revolver and a $1.0 billion USD term loan A. The facilities refinance the prior credit agreement and may be used for working capital, acquisitions, share repurchases and other general corporate purposes. The filing describes a larger committed borrowing base and new covenants, which matter to shareholders because the debt is secured by substantially all assets of the company and key subsidiaries.
Total new facilities of $3.0 billion: $2.0 billion revolver and $1.0 billion term loan A, maturing November 4, 2031
Interest margins range from 1.250% to 1.750% over benchmark rates, tied to Total Net Leverage Ratio; base rate margins 0.250% to 0.750%
Financial covenants include maximum Secured Net Leverage Ratio of 3.75 to 1.00 and minimum Consolidated Interest Coverage Ratio of 3.00 to 1.00
Facilities may be increased by the greater of $618 million and 100% of consolidated EBITDA, subject to leverage tests
SmartKem and Ferrox Critical Minerals agreed on October 30, 2026 to extend the maturity dates of three convertible promissory notes issued by Ferrox to SmartKem, totaling $9.1 million in original principal. All three notes now mature on June 30, 2027, instead of dates between October 30, 2026 and January 31, 2027; the other note terms are unchanged.
Original principal: $1.5 million (March 13, 2026 note), $2.7 million (June 22, 2026 note), $4.9 million (July 27, 2026 note)
Maturity extended to June 30, 2027 for each note, from October 30, 2026, December 31, 2026 and January 31, 2027 respectively
All other terms of the notes remain unmodified, according to the filing
Westinghouse Air Brake Technologies completed a $500 million offering of 5.900% senior notes maturing February 25, 2037. The company plans to use the proceeds, along with revolver, short-term and commercial paper funding, to repay its 3.45% senior notes due November 15, 2026. The filing adds long-term debt but describes it as refinancing existing maturing debt, and the filing does not report earnings or guidance.
Notes: $500 million aggregate principal, 5.900% coupon, maturing February 25, 2037
Interest payable semi-annually on February 25 and August 25, starting February 25, 2027
Proceeds intended to repay 3.45% senior notes due 2026 at maturity on November 15, 2026
Change of control triggers an offer to repurchase at 101% of principal; notes are unsecured and guaranteed by subsidiaries
Carrier Global completed an underwritten offering of $750 million of 5.000% notes due 2029 and $750 million of 5.350% notes due 2033, totaling $1.5 billion. The company plans to use the net proceeds mainly to refinance existing debt, including repaying its 2.493% notes due February 15, 2027, with any remainder for general corporate purposes.
Offering totals $1.5 billion: $750 million of 5.000% notes due November 4, 2029 and $750 million of 5.350% notes due November 4, 2033
Proceeds intended to repay at maturity the 2.493% notes due February 15, 2027, and for general corporate and working capital purposes
Notes are unsecured senior obligations; interest paid semi-annually on May 4 and November 4, starting May 4, 2027
Holders can require repurchase at 101% of principal upon a change of control triggering event
C.H. Robinson Worldwide disclosed amendments dated November 2, 2026, to its existing credit agreement with U.S. Bank National Association as administrative agent and to its note purchase agreement with noteholders. The filing does not state new borrowing amounts, interest rates or maturities, so the size and terms of the changes cannot be determined from this document.
Sixth Omnibus Amendment, dated November 2, 2026, amends a credit agreement originally dated October 29, 2012, with U.S. Bank National Association as administrative agent.
Fourth Amendment to Note Purchase Agreement, dated November 2, 2026, was entered into with noteholders and guarantors.
Certain schedules and exhibits were omitted under Item 601(a)(5) of Regulation S-K and will be provided to the SEC on request.
BWX Technologies said it launched a private offering of $500 million of senior notes due 2034 and, separately, cash tender offers for its two outstanding $400 million series of 4.125% senior notes due 2028 and 2029. The company plans to use the new notes' proceeds, with cash on hand, to buy back the older notes and satisfy and discharge the related indentures, which would refinance existing debt rather than add a stated amount of new debt beyond the $500 million offering.
Private offering of $500 million aggregate principal of senior unsecured notes due 2034, guaranteed by certain wholly-owned subsidiaries
Tender offers cover any and all of the $400 million 4.125% notes due 2028 and $400 million 4.125% notes due 2029
Offers and consent solicitations expire at 5:00 p.m. New York City time on November 10, 2026; settlement expected November 13, 2026
Consents sought would eliminate substantially all restrictive covenants and certain events of default in each indenture
McGrath RentCorp issued and sold $75 million of 6.53% unsecured Series H Senior Notes on November 2, 2026, under an amended note purchase agreement. The amendment also raised the company's revolving private shelf facility to $350 million and increased default thresholds from $10 million to $20 million, which gives the company more borrowing capacity and room before cross-default triggers.
Notes: $75 million principal, 6.53% interest, maturing November 2, 2031
Shelf facility capacity increased to $350 million, less notes outstanding and accepted but not yet issued
Cross-default and judgment thresholds raised from $10 million to $20 million
Company may prepay notes at 100% of principal plus a make-whole amount
Narragansett Bancorp, Inc. completed the two-tier holding company reorganization of BayCoast Bank and its related stock offering, which closed on November 2, 2026. The company sold 9,098,800 shares, and its common stock began trading on the Nasdaq Capital Market under the symbol NARA the same day. The filing reports 21,160,000 shares outstanding after the transaction, which sets the share count that existing and new holders will own.
Offering closed November 2, 2026; 9,098,800 shares sold, including 761,760 shares to the Bank's Employee Stock Ownership Plan
Additional shares issued: 11,638,000 to Narragansett Financial Corporation (mutual holding company) and 423,200 to BayCoast Charitable Foundation, Inc.
Total shares outstanding after closing: 21,160,000; trading began November 2, 2026 on Nasdaq under NARA
DRS book-entry statements and interest checks are expected to be mailed on or about November 4, 2026
Textron issued and sold $350 million principal amount of 5.500% Notes due March 15, 2032, under its existing S-3 shelf registration, with the underwriting agreement dated November 2, 2026. The filing is a debt financing that adds $350 million to the company's borrowings, and it does not report earnings, guidance or a change in operations.
Notes: $350 million principal amount, 5.500% coupon, due March 15, 2032
Issued November 4, 2026 under Form S-3 (No. 333-293711) and a prospectus supplement dated November 2, 2026
BofA Securities, Inc. and Citigroup Global Markets Inc. acted as underwriters' managers
CRH plc said its subsidiary CRH America Finance, Inc. has started cash tender offers for Arcosa, Inc. notes and exchange offers for up to $1.0 billion of new CRH America Finance notes, following CRH's acquisition of Arcosa completed October 23, 2026. Arcosa is also soliciting consents to amend the indentures governing those notes, which would eliminate certain covenants, restrictive provisions, events of default and guarantee provisions. The offers are conditioned on proceeds from a concurrent public offering of senior debt by CRH America Finance, guaranteed by CRH plc, and the filing describes this as a refinancing of acquired debt rather than a change in operating results.
Tender offers cover $400 million of 4.375% notes due 2029 and $600 million of 6.875% notes due 2032
Early tender deadline is November 18, 2026; early settlement expected November 20, 2026; offers expire December 4, 2026
Total tender consideration is $983.75 (2029 notes) and $1,035.00 (2032 notes) per $1,000 principal, including a $50 early tender premium
Exchange offers are capped at up to $1,000,000,000 aggregate principal of new CRH America Finance notes guaranteed by CRH plc
Enova International announced a proposed offering of up to $600 million in senior notes due 2031 and a conditional full redemption of its outstanding 11.25% senior notes due 2028, which total about $400 million. The redemption is conditioned on receiving proceeds from new financing and is set for December 15, 2026, at 102.813% of principal plus accrued interest. The filing does not report earnings or guidance, so the effect on shareholders depends on how the refinancing is completed.
Proposed offering of up to $600 million in senior unsecured notes due 2031, subject to market conditions
Conditional full redemption of about $400 million of 11.25% senior notes due 2028 on December 15, 2026
Redemption price is 102.813% of principal plus accrued and unpaid interest
Company may delay or rescind the redemption if financing conditions are not met by the redemption date
Clarivate's subsidiary, Clarivate Science Holdings Corporation, has started cash tender offers to buy back certain senior notes, subject to a $500 million aggregate cap. The offers expire November 10, 2026, with settlement expected November 13, 2026, and the filing gives no financial results.
Offers cover the 3.875% Senior Secured Notes due 2028 (up to $400 million cap, $750 million outstanding) and the 4.875% Senior Notes due 2029 (up to $100 million cap, $900 million outstanding)
2029 Notes tender consideration is fixed at $928.75 per $1,000 principal amount; 2028 Notes price is set by a fixed spread of +50 basis points over a Treasury reference yield on November 10, 2026
Citigroup Global Markets Inc. is dealer manager; Global Bondholder Services Corporation is tender and information agent
AeroVironment signed a Sixth Amendment to its credit agreement on October 30, 2026, increasing aggregate revolving commitments by $100 million, from $350 million to $450 million, and adding BMO Bank N.A. as a new lender. The facility still matures on October 4, 2029, and remains secured by substantially all company and guarantor assets, so the change expands borrowing capacity without a stated new term loan or change in maturity.
Revolving commitments rise by $100 million, from $350 million to $450 million, under the Sixth Amendment dated October 30, 2026
Earlier Fifth Amendment dated October 9, 2026 raised the letter of credit sublimit from $25 million to $150 million
Revolving facility matures October 4, 2029; obligations remain secured by substantially all assets of the company and guarantors
WEC Energy Group entered into an underwriting agreement on November 2, 2026, to issue and sell $1.0 billion of 6.750% Series 2026A notes and $1.0 billion of 6.950% Series 2026B notes, both junior subordinated and due 2057. The offering is registered under a Form S-3 and is a debt financing, so it adds $2.0 billion of long-term junior subordinated debt rather than changing equity.
Series 2026A: $1.0 billion principal, 6.750% fixed-to-fixed reset rate, due 2057
Series 2026B: $1.0 billion principal, 6.950% fixed-to-fixed reset rate, due 2057
Underwriters include Citigroup Global Markets, J.P. Morgan Securities, RBC Capital Markets, TD Securities and Wells Fargo Securities
Agreement dated November 2, 2026; 8-K filed November 4, 2026
reAlpha Tech Corp. (Nasdaq: AIRE) priced a best efforts public offering of common stock and pre-funded warrants, with gross proceeds expected to be about $1.75 million before fees and expenses. Closing is expected on or about November 4, 2026, and the company plans to use the proceeds for working capital and general corporate purposes, including possible litigation settlements. The new shares and warrant shares would add to the shares outstanding, which could dilute existing shareholders.
Offering includes 1,361,028 shares at $0.40 each and pre-funded warrants for 3,013,972 shares at $0.3999 each, totaling 4,375,000 shares.
Gross proceeds are expected to be approximately $1.75 million, before placement agent fees and other offering expenses.
Maxim Group LLC is the placement agent, with a cash fee of 6.0% of gross proceeds plus up to $150,000 for counsel and out-of-pocket expenses.
The company agreed not to issue new common stock or variable rate transactions for 180 days after closing; directors and executive officers agreed to a 45-day lock-up.
TeraWulf's subsidiary Raylan Data LLC has a 20-year lease with Anthropic for about 401 MW of computing capacity at the Hawesville, Kentucky campus. On November 4, 2026, Google agreed to backstop certain Anthropic lease obligations, which TeraWulf says supports debt financing for the project, and the company also signed a definitive construction agreement with Fluor. Shareholders would see a larger effect if Google exercised its termination-fee option, which would give Google an equity interest in Raylan.
Google backstops certain Anthropic obligations under three Justified Leases (CB-1, CB-2 and CB-3), effective when the final data hall commences.
If Anthropic defaults or becomes insolvent, Google may pay rent and assume the lease, or pay a termination fee that would give Google an equity interest in Raylan.
Anthropic lease covers approximately 401 MW of critical IT load, with phased delivery expected from late 2027 through the second quarter of 2028.
Fluor Enterprises signed a definitive EPC agreement covering engineering, procurement and construction for three data center buildings at Justified.
Carnival Corporation established a commercial paper program on November 3, 2026, allowing it to issue short-term, unsecured notes with an aggregate outstanding limit of $2.0 billion. The notes carry maturities of up to 180 days and are guaranteed by Carnival UK Ltd., with proceeds expected for general corporate purposes. The filing gives no pricing, usage amounts, or changes to earnings, so the program's direct effect on shareholders depends on how much the company borrows under it.
Program allows notes outstanding of up to $2.0 billion at any time, with amounts that can be borrowed, repaid and re-borrowed.
Notes mature in up to 180 days and rank equally with the company's other unsecured, unsubordinated debt.
The company plans to use its revolving credit facility as a liquidity backstop for borrowings under the program.
Dealer agreements and an issuing and paying agent agreement govern the program; the form of dealer agreement is filed as Exhibit 10.1.
Arrowhead Pharmaceuticals refinanced its senior secured term loans on November 2, 2026, replacing a 15.0% payment-in-kind facility with a $400.0 million term loan at three-month Term SOFR plus 5.50% that matures November 2, 2031. The existing loans were repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, a discount of about $68 million from the 2.0x MOIC payment otherwise owed, and the new terms remove required prepayments from plozasiran sales and licensing proceeds. For shareholders, the filing shows lower interest cost, a longer maturity and fewer mandatory repayments, while the company now carries a $400.0 million secured obligation.
New $400.0 million senior secured term loan matures November 2, 2031, with interest at three-month Term SOFR (1.00% floor) plus 5.50%, versus a fixed 15.0% rate paid in kind on the retired loans
Existing loans repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, which included a discount of about $68 million from the 2.0x MOIC payment
Minimum unrestricted cash covenant reduced to $125.0 million from $150.0 million
New agreement no longer requires prepayment from plozasiran sales, royalties, milestones or pipeline monetizations; the filing says the terms are to be filed with the 10-Q for the quarter ended December 31, 2026
On October 30, 2026, Flutter Entertainment plc and certain subsidiaries entered into a First Amendment and Restatement Agreement to their Credit Agreement, extending the term A facilities and revolving credit facility maturity to May 3, 2032. The revolver commitments increase to $1.86 billion, its base currency changes from sterling to U.S. dollars, and the term A loans are redenominated into U.S. dollars and euros. The filing also replaces the net total leverage covenant with a net first lien leverage covenant set at 5.70:1.00.
Maturity of term A facilities and revolver extended to May 3, 2032
Revolver commitments increased to $1.86 billion; base currency changed from sterling to U.S. dollars
Outstanding term A loans: €382 million of term A2 loans and $1,374 million of term A3 loans; no sterling term A loans remain
Loans priced at Term SOFR, EURIBOR or SONIA plus a margin of 1.40% to 2.00%, based on corporate ratings
On October 29, 2026, NESR and certain subsidiaries satisfied the conditions to a new 2026 Secured Facilities Agreement with a syndicate of lenders, which refinances existing secured credit facilities and funds operations and working capital. Total facilities at inception were approximately $747.1 million, and the company terminated its 2021 Secured Facilities Agreement in connection with the new deal. The agreement sets leverage and coverage covenants and restricts dividends and other shareholder distributions unless the covenants are met on a pro forma basis.
Total facilities of approximately $747.1 million: $298.1 million in term loans, a $5.0 million revolving credit facility and approximately $444.0 million in uncommitted working capital facilities
Term loans are repayable in scheduled installments over a 36-month term, with remaining principal due at maturity in October 2029
Financial covenants require a maximum Total Net Debt to EBITDA ratio of 2.00, a debt service coverage ratio above 1.25 and an interest coverage ratio of at least 4.00
The company terminated its 2021 Secured Facilities Agreement in connection with the new agreement
On October 28, 2026, Stewards, Inc. sold an unsecured convertible promissory note with a principal amount of $6,050,000 to Crom Structured Opportunities Fund I, LP for $5,500,000. The note matures in 12 months, and the investor can convert it into common stock from January 31, 2027, at 90% of the lowest daily VWAP over the prior five trading days, which could add substantial dilution for shareholders. The company plans to use about $4,937,000 in net proceeds to fund its proposed acquisition of PIXL, LLC, though no definitive agreement has been signed.
Note: $6,050,000 principal, $5,500,000 purchase price, 10% original issue discount, due in 12 months
Conversion from January 31, 2027 at 90% of the lowest five-day VWAP, with a full-ratchet anti-dilution adjustment
Share reserve of at least 7,000,000 shares; issuance above 45,309,740 shares (19.99%) requires stockholder approval, given by majority holders by written consent on October 28, 2026
Placement agent E.F. Hutton & Co. received a $440,000 cash fee and warrants for 121,109 shares at $2.498
Wabtec priced a $500 million offering of 5.900% Senior Notes due 2037 on November 2, 2026. The company plans to use the proceeds, together with borrowings under its revolving credit facilities, short-term facilities and/or commercial paper, to repay its 3.450% Senior Notes due November 15, 2026. The sale is expected to close on November 4, 2026.
Offering: $500 million aggregate principal of 5.900% Senior Notes due February 25, 2037, priced November 2, 2026
Use of proceeds: repay the 3.450% Senior Notes due 2026 at maturity on November 15, 2026, alongside other borrowings
Expected closing: November 4, 2026, subject to customary closing conditions
Joint book-running managers: BofA Securities, Citigroup Global Markets, PNC Capital Markets and TD Securities
AH Realty Trust's operating partnership entered new credit agreements on October 28, 2026, providing a $150.0 million revolving credit facility and three term loans totaling $500.0 million, which replace four prior loan facilities. The filing also describes a separate $121.8 million secured term loan for subsidiaries that own the Constellation Tower property, with the financing terms and covenants taking effect for shareholders as a refinancing of existing debt.
On October 28, 2026, the operating partnership signed a Fourth Amended and Restated Credit Agreement with Bank of America, N.A. as administrative agent, including a $150.0 million revolver maturing October 28, 2031, a $200.0 million 4-year
A separate $100.0 million 7-year term loan maturing October 28, 2033 was arranged with Toronto Dominion (Texas) LLC, with an accordion feature allowing increases up to $250.0 million maximum outstanding.
The new loans replace a $355.0 million revolver, a $350.0 million term loan, a $135.0 million term loan with Manufacturers and Traders Trust Company, and a $95.0 million term loan with Toronto Dominion (Texas) LLC.
Constellation subsidiaries entered a $121.8 million term loan maturing October 28, 2029 with PNC Bank, N.A., priced at Daily Simple SOFR plus 1.80% and secured by the Constellation Tower property.
Acadia Realty Trust filed a new automatic shelf registration on Form S-3 to replace its 2023 shelf, which expires November 7, 2026, and amended its at-the-market equity offering program. The amendment adds Citizens JMP Securities as an additional sales agent and forward purchaser, and about $199 million remains available under the program. The filing describes routine capital-raising housekeeping, and it signals that the company can issue new common shares under the program, which would dilute existing holders if used.
New automatic shelf registration on Form S-3 filed November 3, 2026, replacing the 2023 shelf that expires November 7, 2026
Amendment No. 1 covers common shares with an aggregate sale price of up to $500 million under the at-the-market program
As of the amendment date, up to $199,062,233.91 in common shares remained available for issuance under the program
Citizens JMP Securities, LLC added as an additional sales agent and forward purchaser
On November 3, 2026, Procter & Gamble closed an underwritten public offering of four series of euro-denominated notes under its existing Form S-3 shelf registration, totaling €3.25 billion in principal. The notes mature between 2030 and 2046 and carry coupons from 3.750% to 4.625%, so the offering adds long-term debt to the company's balance sheet.
Four tranches: €750 million due November 3, 2030 at 3.750%; €1.0 billion due November 3, 2034 at 4.100%; €750 million due November 3, 2038 at 4.250%; €750 million due November 3, 2046 at 4.625%
Offering closed on November 3, 2026, under Registration No. 333-299472
Legal opinions filed as Exhibits 5(a) and 5(b); the filing does not state the use of proceeds
Enova International furnished a Form 8-K disclosing a proposed private offering of $500,251,000 in Series 2026-2 fixed rate asset-backed notes by subsidiary OnDeck Asset Securitization IV, LLC, backed by small business loans from OnDeck. The filing also furnishes supplemental historical loan performance data made available to potential note purchasers, and the notes will not be obligations of or guaranteed by Enova or OnDeck, so shareholders' direct exposure is limited to the terms and completion of the offering.
Proposed offering of $500,251,000 aggregate principal amount of Series 2026-2 Fixed Rate Asset-Backed Notes by OnDeck Asset Securitization IV, LLC
Issuer is sole obligor; notes are not obligations of, or guaranteed by, Enova or OnDeck
Notes offered only to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S; terms and timing depend on market conditions
Supplemental data was made available to potential purchasers on November 3, 2026, covering term loans and lines of credit with original terms of 24 months or less and minimum loan yields of at least 10%
On November 3, 2026, H2O America issued and sold 7,475,000 corporate units under an October 29, 2026 underwriting agreement with Wells Fargo Securities and J.P. Morgan Securities as representatives. Each unit combines a stock purchase contract requiring the holder to buy common stock by November 1, 2029 with a 1/20 interest in $1,000 of 5.300% remarketable senior notes due 2031, so the sale may lead to new common shares being issued.
7,475,000 corporate units sold, including 975,000 units from the full exercise of the underwriters' over-allotment option.
Each unit has a $50 stated amount; the stock purchase contract is due no later than November 1, 2029, for $50 in cash per contract.
Total annual distributions are 7.750% of the stated amount: 2.450% in contract adjustment payments and 5.300% in note interest.
The senior notes will be remarketed before the stock purchase contract settlement date, under a remarketing agreement not yet signed as of the filing.
Blue Acquisition Corp, a Cayman Islands blank-check company, issued an unsecured, non-interest-bearing promissory note of up to $50,000 to director Dario Dino Ferrari to fund working capital. The note is repayable only upon completion of its proposed business combination with Blockfusion USA, Inc. or on liquidation, and repayment outside the trust account is limited to any funds remaining there, which is a modest financing step with limited dilution-free funding for shareholders.
Unsecured promissory note issued November 3, 2026, for up to $50,000 to director Dario Dino Ferrari
Note bears no interest; principal due on the earlier of the Blockfusion business combination or liquidation
Payee waives claims against the trust account; repayment otherwise limited to funds outside the trust, if any
Sands China, a majority-owned subsidiary of Las Vegas Sands, completed a $1.0 billion private offering of senior unsecured notes on November 3, 2026. The company said it intends to use the proceeds and cash on hand to redeem its $700 million 2.300% notes due 2027, repay its 2024 SCL Revolving Facility balance, and for general corporate purposes. The filing does not state a direct effect on Las Vegas Sands' reported results, but the new debt is an obligation of its Hong Kong-listed subsidiary.
$700 million of 6.400% Senior Notes due 2032 and $300 million of 6.700% Senior Notes due 2033, totaling $1.0 billion
Notes mature January 8, 2032 and November 8, 2033; both are listed on The Stock Exchange of Hong Kong
Proceeds, with cash on hand, intended to redeem in full the $700 million 2.300% notes due 2027 and repay the 2024 SCL Revolving Facility balance
Notes are unguaranteed by Sands China's subsidiaries and structurally subordinated to their liabilities
Radian Group's UK subsidiary ICML amended and restated its letter of credit facility with a syndicate of banks led by Barclays, raising lender commitments from $620 million to $880 million. Radian Group is now guarantor of ICML's obligations, replacing Inigo Limited, and the facility supports ICML's Lloyd's underwriting for the 2027 year of account and prior open years. The facility carries financial covenants and cross-default risk to Radian Group's revolving credit facility and senior notes.
Lender commitments increased from $620 million to $880 million, effective October 29, 2026
Radian Group added as guarantor; Inigo Limited removed as guarantor
Letters of credit have a minimum term of four years and expire no later than December 31, 2030
Covenants include minimum consolidated net worth and maximum Debt-to-Total Capitalization; a default could trigger defaults under Radian Group's RCF and senior notes
Liminatus Pharma agreed on November 2, 2026 to sell 260,001 common shares at $2.50 each in a private placement to a non-U.S. investor, raising gross proceeds of $650,002.50. The company plans to use the proceeds for working capital and general corporate purposes, with closing expected on or about November 20, 2026. The company also agreed to file a resale registration statement within 60 days of closing, which could add shares that may be sold into the market later.
Shares: 260,001 common shares at $2.50 per share
Gross proceeds: $650,002.50, for working capital and general corporate purposes
Expected closing: on or about November 20, 2026
Company must file a resale registration statement with the SEC within 60 days of closing
Bunge Global SA and certain subsidiaries amended their existing trade receivables securitization program on October 30, 2026, extending its termination date by 364 days to December 13, 2027. The filing says other key terms were substantially unchanged and does not disclose a dollar size for the program.
Amendment dated October 30, 2026 extends the program's termination date by 364 days to December 13, 2027.
Purchasers permitted a merger of one Dutch originator into another Dutch subsidiary, which survives as a Dutch originator.
Bunge's recourse is limited to its first loss position as subordinated lender, apart from repurchase obligations for ineligible receivables.
BWX Technologies entered into an amendment to its existing credit agreement with Wells Fargo as administrative agent and other lenders. The amendment extends the maturity of the $1.25 billion senior secured revolving credit facility by one year to November 10, 2031, and changes the interest coverage covenant and pricing terms.
Maturity of the $1.25 billion senior secured revolving credit facility extended one year to November 10, 2031
Minimum interest coverage ratio no longer applies if no default exists and the company obtains investment grade ratings (stable outlook or better) from at least two designated rating agencies
Pricing grid set to the lower of the existing leverage-based grid or a grid tied to the company's corporate ratings
On November 2, 2026, Ocean Power Technologies entered a Securities Purchase Agreement with Vanquish Funding Group and issued a 12% promissory note with a principal of $373,750 for a purchase price of $325,000, with up to $2,875,000 in additional tranches possible over the next twelve months, subject to further agreement. The note's conversion feature applies only after an Event of Default, at 75% of the lowest closing bid price over the prior ten trading days, which could lead to dilution for shareholders.
Note principal of $373,750 issued for a $325,000 purchase price, including a $48,750 original issue discount; matures October 30, 2027
Up to $2,875,000 in additional financing tranches possible over the next twelve months, subject to further agreement
Conversion into common stock is possible only after an Event of Default and not before 180 days after issuance, at 75% of the lowest closing bid price over the prior ten trading days
On default, the company must pay 150% of outstanding amounts plus collection costs; the company is responsible for $7,000 of Vanquish's fees
Fathom Holdings signed a Third Omnibus Amendment to its Senior Secured Convertible Promissory Notes with the holders on November 2, 2026. The amendment extends the Maturity Date from November 1 to November 30, 2026, defers accrued interest to the new maturity date, and adds weekly extension fees of 0.5% of outstanding principal. Because the deferred interest and fees add to the amount owed, shareholders face a larger payment due at maturity. The chairman of the board, Scott Flanders, is one of the holders, and the independent directors approved the transaction.
Maturity Date extended from November 1, 2026 to November 30, 2026.
All accrued and unpaid interest is deferred, and the 18% per annum rate continues to apply to outstanding principal.
Weekly extension fee of 0.5% of outstanding principal is due on November 9, 16, 23 and 30, 2026, if principal remains outstanding.
Chairman Scott Flanders is a Holder of one of the Notes; a majority of independent, disinterested directors approved the transaction.
Reed's, Inc. agreed on October 28, 2026 to sell 17,421,602 shares of common stock to D&D Source of Life Holding, Ltd., its majority stockholder, at $0.574 per share, for gross proceeds of approximately $10.0 million, expected to close on or about November 6, 2026. The filing says the proceeds satisfy a minimum cash equity contribution requirement under the company's senior secured loan amendment, and the company intends to use the funds for working capital and general corporate purposes.
Shares priced at $0.574 each; 17,421,602 shares; gross proceeds of approximately $10.0 million
Expected closing on or about November 6, 2026, the same deadline set by the loan amendment
Company must file a resale registration statement within 15 days after closing; target effectiveness within 70 days (90 if SEC conducts a full review)
Shares sold privately under Section 4(a)(2) and Rule 506(b), so they are unregistered
On November 3, 2026, CMS Energy issued and sold $1 billion of 6.800% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2057 under a shelf registration. The company plans to use the net proceeds to repay its $275 million 2.95% Senior Notes due February 2027 and its $350 million 3.45% Senior Notes due August 2027, and for general corporate purposes. The filing mainly adds offering documents as exhibits to the registration statement.
$1,000,000,000 principal of 6.800% junior subordinated notes due 2057 issued November 3, 2026, under shelf registration No. 333-293382
Proceeds earmarked to repay $275 million 2.95% senior notes due February 2027 and $350 million 3.45% senior notes due August 2027, plus general corporate purposes
Estimated offering expenses total $1,800,000, including $1,550,350 in rating agency fees
Underwriters named include Deutsche Bank Securities, J.P. Morgan Securities, Mizuho Securities, Morgan Stanley, MUFG Securities Americas and Wells Fargo Securities
Kairos Pharma amended its equity line of credit purchase agreement with Helena Global Investment Opportunities I Ltd. three times in 2026, changing the purchase price, the pricing period and the period during which the company can use the facility. The company also furnished materials for a November 3, 2026 conference presentation on interim efficacy data for ENV-105. The filing does not state the number of shares or the proceeds involved, but the amendments change the terms under which shares can be sold to Helena, which matters to shareholders.
February 4, 2026: purchase price set at 97% of the average daily VWAP during the Pricing Period.
October 26, 2026: Pricing Period shortened from three Trading Days to one Trading Day.
October 29, 2026: option to use the equity line extended one year to December 31, 2028.
November 3, 2026: President and Chief Scientific Officer Neil Bhowmick presents interim ENV-105 data; median progression-free survival was 17.7 months with the combination versus 2 months with apalutamide alone (P=0.0008).
Bread Financial Holdings issued and sold 5,000,000 depositary shares on November 3, 2026, each representing a 1/40th interest in a share of its 9.375% Series C Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, which has a $1,000 liquidation preference per share. The Series C terms restrict dividends on junior stock and repurchases of parity or junior stock if the company does not declare and pay or set aside dividends on the Series C for the prior dividend period. Holders of the depositary shares receive proportional dividend, voting, redemption and liquidation rights.
5,000,000 depositary shares issued and sold on November 3, 2026, each a 1/40th interest in a Series C preferred share
Series C carries a 9.375% fixed rate reset, non-cumulative perpetual preferred stock with a $1,000 liquidation preference per share
Underwriters hold a 30-day option, from October 27, 2026, to buy up to 750,000 additional depositary shares
Certificate of Designations filed with Delaware on November 2, 2026 and effective November 3, 2026
On October 29, 2026, Weis Markets and its subsidiaries amended their unsecured revolving credit agreement with Wells Fargo Bank. The facility provides a $30 million principal commitment, with an additional $70 million of discretionary availability, and matures on October 1, 2030. The filing says the other terms are consistent with the prior agreement and does not state any amount borrowed under the facility.
Unsecured revolving facility: $30 million aggregate principal commitment plus $70 million discretionary availability.
Maturity date is October 1, 2030; no principal payments are due before maturity.
Loans bear interest at 1.00% above Daily Simple SOFR, and an unused fee of 0.25% applies.
Company must maintain minimum EBITDA of $175 million, tested quarterly on a trailing twelve-month basis.
Indivior's 8-K says a special dividend declared by the board on September 16, 2026 triggered an increase in the conversion rate on its 0.625% Convertible Senior Notes due 2031, from 24.0033 to 30.9355 common shares per $1,000 principal, a conversion price of approximately $32.33 per share. The filing is signed by Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.), and it states that no bondholders converted their notes for common stock.
Special dividend declared by the board on September 16, 2026 triggered the adjustment.
Conversion rate per $1,000 principal increased from 24.0033 to 30.9355 common shares.
Implied conversion price is approximately $32.33 per share.
No bondholders converted their notes for common stock.
Geospace Technologies entered into a three-year, $25 million revolving credit facility with Amerisource Funding on October 29, 2026, and used it to repay and terminate its existing Woodforest credit agreement, which had a $7.5 million outstanding balance. The new facility carries prime plus 3.5% interest, is secured by substantially all borrower assets, and includes a $65.0 million minimum tangible net worth covenant, so shareholders should note the tighter terms and the lender's default provisions.
New Amerisource revolver: $25 million maximum availability, subject to a borrowing base, three-year term
Interest at prime rate plus 3.5% per annum; default rate of 18% per annum if obligations are accelerated
Minimum tangible net worth covenant of $65.0 million; 1.00% annual commitment fee and 0.25% non-usage fee
Woodforest credit agreement, which had a $7.5 million outstanding balance, was repaid and terminated, with no material early termination penalties reported
On November 2, 2026, AEON Biopharma amended its two-year milestone warrants to reduce their exercise price from about $0.32 to $0.20 per share, with holders of at least 67% of the underlying shares agreeing. Certain holders have agreed to exercise at the lower price, and the company expects about $6.2 million in gross proceeds. The amendment applies to all outstanding warrants, which expire on November 16, 2026, after the FDA's September 30 feedback triggered accelerated expiration.
Exercise price cut from $0.3221 to $0.20 per common share, effective November 2, 2026
Company expects approximately $6.2 million in gross proceeds from warrant exercises
Amendment applies to all outstanding Two-Year Warrants; share count and expiration date unchanged
Warrants expire November 16, 2026; 71,517,020 common shares were outstanding as of October 30, 2026
Peraso Inc. completed a private placement to Nant Capital, LLC on October 28, 2026, issuing 3,271,355 shares, pre-funded warrants and common warrants for aggregate gross proceeds of approximately $10.0 million before offering expenses. The filing says the company will use the proceeds for working capital and general corporate purposes, and the warrants could add up to 36,458,481 shares of common stock, which would dilute existing shareholders. The company has also agreed to register the resale of these shares, and the filing lists going concern and Nasdaq listing compliance among its risk factors.
Closing date was October 28, 2026; the Purchase Agreement was signed October 26, 2026.
Shares were sold at $0.5034 each, with pre-funded warrants priced at $0.5024 each, both including a common warrant.
Common warrants have an exercise price of $0.3784 per share and expire October 28, 2028.
A resale registration statement is due by November 27, 2026, with liquidated damages of 1.0% per month, up to 5.0%, if deadlines are missed.
Our Bond, Inc. (OBAI) converted its senior secured loan from Eastward Fund Management and fees owed to Maxim Group into Series G Preferred Stock, and exchanged older Series C and D preferred stock for Series G with Ascent Partners. On November 3, 2026, it also agreed to sell up to $10 million of common stock to an accredited investor, with $250,000 issued at the initial closing. The filing describes dilution-related terms, including conversion price adjustments, resale registration obligations, and leak-out limits on the holders' stock sales, which matter to shareholders because the share count could grow.
Eastward loan obligations of $7,878,149.32 converted into 787,815 Series G Preferred shares; Eastward's Series B-1 Warrants were retired.
Maxim fees of $803,940.82 converted into Series G Preferred shares; Ascent exchanged 52,500 Series C and 525,451 Series D preferred shares for 577,948 Series G shares.
November 3, 2026 private offering: up to $10,000,000 of common stock at $2.75 per share; initial closing issued 90,909 shares for $250,000.
Series G conversion price is $2.0265 per common share, with dividends at 10% annually, rising to 24% after a triggering event.
Cheniere Energy agreed on November 2, 2026 to sell $1.2 billion of 5.800% senior notes due 2037 through Morgan Stanley & Co. LLC as representative of the initial purchasers, and priced the offering that day. The company says proceeds may be used for general corporate purposes, including repaying or refinancing existing debt such as its subsidiary's 5.125% notes due 2027, plus capital expenditures and working capital, which would affect the company's debt profile for shareholders.
Principal amount of $1.2 billion, issued at 99.313% of par, with interest at 5.800% per year.
Notes mature March 15, 2037; closing is expected on November 17, 2026.
Offering is a private sale to qualified institutional buyers under Rule 144A and to persons outside the United States under Regulation S.
Proceeds may repay, refinance or redeem existing debt, including subsidiary Cheniere Corpus Christi Holdings' 5.125% Senior Secured Notes due 2027.
Xcel Energy priced an upsized private offering of $2.2 billion in 2.625% convertible senior notes due December 15, 2027, with an option for up to $300 million more. The company expects net proceeds of about $2.18 billion, to be used mainly to repay short-term borrowings, and expects the sale to close on November 5, 2026. Conversion would be at an initial price of about $87.26 per share, and the company may settle the principal in cash, but share issuance is possible for amounts above principal.
Pricing of $2,200,000,000 of 2.625% convertible senior notes due December 15, 2027, upsized from $2,000,000,000
Initial purchasers have a 13-day option for up to an additional $300,000,000 of notes
Expected net proceeds of about $2,178,500,000, or $2,476,250,000 if the option is fully exercised
Initial conversion price of about $87.26 per share, a 10.0% premium to the last reported sale price on November 2, 2026
Tevogen amended its loan agreement with The Patel Family, LLP, extending the borrowing window to May 31, 2029 and fixing a $7.40 per-share price for share-based repayments. On November 2, 2026, the company repaid the entire $7.4 million principal balance and $177,880 of accrued interest by issuing 1,000,000 principal shares and 23,733 interest shares, eliminating all loan liabilities. The filing also grants CEO Ryan Saadi a 50,000,000-share restricted award that vests only if Tevogen reaches $1.0 billion in aggregate revenue by December 31, 2031.
Loan amended October 27, 2026; borrowing window extended from May 31, 2027 to May 31, 2029; up to $28.6 million remaining available
November 2, 2026: $7.4 million principal and $177,880 interest repaid in 1,000,000 principal shares and 23,733 interest shares
CEO Ryan Saadi granted 50,000,000 restricted shares, vesting only if $1.0 billion aggregate revenue is certified by December 31, 2031
Filing states Saadi held approximately 90.9% of voting power after the grant and repayment
Mid-America Apartment Communities' operating partnership priced a $350 million offering of 5.350% senior unsecured notes due December 15, 2031, at 99.584% of principal. Net proceeds are intended to repay amounts under its revolving credit facility and commercial paper program and for general corporate purposes, with closing expected November 12, 2026. The filing reports no earnings or guidance changes.
Offering size: $350,000,000 aggregate principal amount of 5.350% senior unsecured notes due December 15, 2031
Issue price: 99.584% of principal amount
Expected closing: November 12, 2026, subject to customary closing conditions
Use of proceeds: repay revolving credit facility and commercial paper borrowings, plus general corporate purposes
Science Applications International Corp. priced a private offering of $500 million in 6.75% senior notes due 2034, upsized from the $400 million it first announced, at 100% of principal. The company plans to use the net proceeds to redeem all of its outstanding 4.875% Senior Notes due 2028, which refinances existing debt and does not change the company's reported results. The offering is expected to close on or about November 13, 2026, subject to customary closing conditions.
Priced $500 million of 6.75% senior notes due 2034 at 100% of principal, up from the $400 million announced at launch
Net proceeds to redeem all outstanding 4.875% Senior Notes due 2028, with any remainder for general corporate purposes
Redemption of the 2028 Notes is conditioned on closing of the offering
HCA Healthcare's wholly owned subsidiary, HCA Inc., proposed a public offering of senior unsecured notes on November 2, 2026, with terms to depend on market conditions. The subsidiary also gave notice it will redeem all $1.200 billion of its 4.500% senior notes due February 2027 on December 2, 2026, conditioned on receiving offering proceeds, which may also repay commercial paper and credit facility borrowings.
Proposed offering of senior unsecured notes by HCA Inc.; maturity, interest rate and principal amount not yet set
Notice given November 2, 2026 to redeem all $1.200 billion of 4.500% senior notes due February 2027 on December 2, 2026
Net proceeds may be used for general corporate purposes, including the redemption, repaying up to $8.000 billion commercial paper program borrowings, and repaying senior unsecured credit facility borrowings
Blackstone's subsidiary Blackstone Reg Finance Co. L.L.C. completed a $1.1 billion offering of senior notes, with $600 million of 5.650% notes due 2031 and $500 million of 5.900% notes due 2033. The notes are fully guaranteed by Blackstone Inc. and several of its subsidiaries, so they add to the group's debt obligations, and the company says the proceeds will fund general corporate purposes.
$600 million of 5.650% senior notes mature November 3, 2031
$500 million of 5.900% senior notes mature November 3, 2033
Interest is payable semiannually on May 3 and November 3, starting May 3, 2027
Blackstone intends to use the proceeds for general corporate purposes
On October 27, 2026, Inuvo exchanged $1.2 million of principal on its Secured Promissory Note B for a Secured Promissory Note A-2 with a principal amount of $1,308,000, held by Streeterville Capital, LLC. The new note carries 9.00% interest, is due June 29, 2028, and lets the lender demand cash redemptions from March 2027 and, from December 29, 2026, when the share price is at least 10% above the NYSE Minimum Price. Trigger events can increase the balance and lead to default with a rate of up to 15%, which adds cost and repayment pressure for shareholders.
A-2 note principal of $1,308,000, due June 29, 2028, at 9.00% annual interest
Lender may redeem up to $750,000 per calendar month starting March 29, 2027
Limited Redemptions up to 8% of cumulative daily dollar trading volume may begin December 29, 2026, if shares trade at least 10% above the NYSE Minimum Price
Major and minor trigger events can raise the balance by 10% and 5%; uncured events can become defaults with a rate of up to 15%
Aspen Neuroscience, Inc. completed its initial public offering on November 2, 2026, selling 9,375,000 shares of common stock at $15.00 per share. The company said gross proceeds were approximately $140.6 million, before underwriting discounts, commissions and offering expenses. Its amended and restated certificate of incorporation and bylaws also took effect on the same date.
IPO of 9,375,000 common shares at $15.00 per share, completed November 2, 2026
Gross proceeds of approximately $140.6 million, before underwriting discounts and offering expenses
Amended and restated certificate of incorporation and bylaws became effective at closing
Registration Statement on Form S-1 was filed October 9, 2026; final prospectus filed October 30, 2026
On November 2, 2026, Procter & Gamble closed an underwritten public offering of $352,231,000 in aggregate principal amount of Floating Rate Notes due November 2, 2076, sold under its existing Form S-3 registration statement. The filing is administrative, attaching legal opinions for the notes and no new financial results or guidance.
Offering closed November 2, 2026: $352,231,000 aggregate principal amount of Floating Rate Notes
Notes mature November 2, 2076, under Registration No. 333-299472
Filing attaches legal opinions (Exhibits 5(a) and 5(b)) and consents; no earnings or guidance included
AVITA Medical disclosed that Perceptive Credit Holdings V exercised a warrant on October 26, 2026 through a cashless exercise, with the company withholding 112,284 shares to cover the exercise price and issuing 387,716 shares on October 28, 2026. The warrant was tied to a January 13, 2026 credit agreement and covered up to 500,000 shares, so the issuance adds new common shares outstanding for existing holders.
Perceptive exercised the warrant on October 26, 2026 via a cashless exercise.
The company withheld 112,284 shares to cover the exercise price.
The company issued 387,716 shares to Perceptive on October 28, 2026, out of a warrant for up to 500,000 shares.
The filing was lodged on the Australian Securities Exchange on November 2, 2026.
UGI Corporation entered into a Second Amendment to its Credit Agreement on October 28, 2026, raising its revolving commitments from $475 million to $700 million and extending maturities to March 31, 2030. The amendment also adds a new $300 million senior secured revolving loan facility, which can be used to fund cash consideration due on a conversion of the 2028 Notes.
Existing revolving commitments increased from $475 million to $700 million
Revolving and term loan maturities extended to March 31, 2030, with a springing maturity 91 days before the 2028 Notes mature if more than $210 million of those notes remain outstanding
New $300 million senior secured revolving loan facility, with a June 30, 2027 maturity subject to a one-time one-year extension
Loans are secured by a pledge of equity in Material Subsidiaries, excluding UGI Utilities, Inc. and Mountaintop Energy Holdings LLC
KeyCorp issued $1,000,000,000 of 5.889% Fixed-to-Floating Rate Senior Medium Term Notes, Series U, due November 2, 2032, on November 2, 2026, under a registration statement on Form S-3. The filing is a routine debt issuance and includes a legal opinion from Squire Patton Boggs (US) LLP on the validity of the notes.
Principal amount: $1,000,000,000 in senior medium term notes, Series U
Interest: 5.889% fixed-to-floating rate; maturity date November 2, 2032
Issued under Form S-3 registration statement (File No. 333-296536)
Legal opinion from Squire Patton Boggs (US) LLP filed as Exhibit 5.1
FTAI Aviation's subsidiary priced a $1.0 billion private offering of 7.125% senior notes due 2034. Proceeds are planned to repay the revolving credit facility used to fund the company's accelerated share repurchase program and to redeem $500.0 million of 5.50% senior notes due 2028.
Notes: $1.0 billion aggregate principal, 7.125% per annum, issued at 100% of principal, due 2034
Use of proceeds: repay all revolving credit facility amounts, redeem $500.0 million of 2028 Notes, pay fees and expenses
Notes are senior unsecured and guaranteed by FTAI Aviation and eligible subsidiaries; offered only to qualified institutional and non-U.S. buyers
Workhorse Group entered into Amendment No. 4 to its Cash Flow Credit Agreement and Amendment No. 3 to its Customer Order Credit Agreement, both with lender Motive GM Holdings II LLC, dated October 27, 2026. The amendments raise the Customer Order commitment from $20 million to $30 million and defer interest payments on the additional $10 million loans until after March 31, 2027, which adds to the company's borrowing from its lender.
Customer Order Credit Agreement commitment increases from $20,000,000 to $30,000,000.
Interest on the additional $10,000,000 loan is deferred until the first Interest Payment Date after March 31, 2027.
Cash Flow Credit Agreement interest on additional $10,000,000 loans from three earlier amendments is also deferred to after March 31, 2027.
Amendments were dated October 27, 2026, and the filing was signed November 2, 2026 by CFO Jody Davis.
On October 27, 2026, a Diversified Energy subsidiary signed an amendment to its revolving credit agreement. The amendment raises the borrowing base from $900 million to $1 billion and the aggregate maximum credit amounts from $1.5 billion to $2.5 billion, while cutting interest margins by 25 basis points. It also sets an earlier maturity date if the Nordic bonds remain outstanding, which would move the facility's maturity to January 8, 2029.
Borrowing base rises from $900 million to $1 billion; aggregate maximum credit amounts rise from $1.5 billion to $2.5 billion.
Truist Bank replaces KeyBank National Association as administrative agent; KeyBank is no longer a lender.
Interest margins are reduced by 25 basis points; maturity moves to October 27, 2030, or earlier, to January 8, 2029, if the 9.75% Nordic bonds due April 9, 2029 remain outstanding.
On October 26, 2026, ABS IX redeemed its $62 million in asset-backed notes using borrowings under the credit agreement.
Southwest Airlines completed a public offering of $1.25 billion in senior debt notes on November 2, 2026. The notes are split into $600 million of 5.750% notes due 2029 and $650 million of 6.000% notes due 2031, adding new borrowing obligations to the company's balance sheet.
Total offering of $1,250,000,000 in debt securities completed November 2, 2026
$600 million of 5.750% Notes due 2029 and $650 million of 6.000% Notes due 2031
Notes issued under a February 6, 2024 indenture with U.S. Bank Trust Company, National Association, as trustee
Underwriters named in the filing include Barclays Capital Inc., BNP Paribas Securities Corp., Standard Chartered Bank, U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC
Avis Budget Car Rental, LLC and Avis Budget Finance, Inc., wholly-owned subsidiaries of Avis Budget Group, Inc., sent notice on November 2, 2026 that they will redeem all $350 million of their outstanding 5.750% Senior Notes due July 2027. The notes will be repaid in full on December 30, 2026 at 100% of principal plus accrued and unpaid interest. The filing is a debt repayment notice that does not report any change to earnings or guidance.
Redemption of all $350 million aggregate principal of 5.750% Senior Notes due July 2027
Redemption price is 100% of principal amount, plus accrued and unpaid interest to the Redemption Date
WhiteHawk Minerals Corp. disclosed a Third Amendment to its Amended and Restated Credit Agreement, signed October 27, 2026, with Capital One, National Association, as administrative agent. The amendment removes a reference to Series D Preferred Stock and expressly permits the Series E and Series F Preferred Stock, with the Series F issuance conditioned on the first $50.0 million of net proceeds redeeming the Series E Preferred Stock in full.
Third Amendment dated October 27, 2026 amends the credit agreement dated May 25, 2026
Series F Preferred Stock issuance is conditioned on the first $50.0 million of net cash proceeds redeeming Series E Preferred Stock in full
Series D Preferred Stock reference removed from the credit agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.